

## PRIOR AUTHORIZATION CRITERIA

This list is current as of 3/1/2024 and pertains to the following formularies:

2024 Independent Health's Medicare Advantage C-SNP Part D Formulary	Version 9
---	-----------

Independent Health requires you (or your physician) to get prior authorization for certain drugs. This means that you will need to get approval from us before you fill your prescriptions. If you do not get approval, we may not cover the drug. These drugs are listed with a "PA" in the Requirements/Limits column on the formularies. This document contains the Prior Authorization requirements that are associated with our Medicare Advantage Part D formularies.

If you have any questions, please contact our Medicare Member Services Department at 1-800-665-1502 or, for TTY users 711, October 1<sup>st</sup> – March 31<sup>st</sup>: Monday through Sunday from 8 a.m. to 8 p.m., April 1<sup>st</sup> – September 30<sup>th</sup>: Monday through Friday from 8 a.m. to 8 p.m.

The formulary may change at any time. You will receive notice when necessary.

## ABILIFY MYCITE (aripiprazole with sensor)

### Products Affected

- ABILIFY MYCITE MAINTENANCE KIT ORAL TABLET THERAPY PACK 10 MG, 15 MG, 20 MG, 30 MG, 5 MG
- ABILIFY MYCITE STARTER KIT ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	Dementia-related psychosis
Required Medical Information	Diagnosis of covered use, documentation of previous aripiprazole use (see Other Criteria).
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. For approval, the patient must have documentation of at least a one-month trial of generic aripiprazole solution, tablets, or orally-disintegrating tablets.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ACTIMMUNE (interferon gamma-1b)

---

### Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# ADEMPAS (riociguat)

## Products Affected

- ADEMPAS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Pregnancy, severe (Child-Pugh class C) hepatic impairment, creatinine clearance below 15 mL/min or on dialysis, concurrent use with nitrates or nitric oxide donors in any form, concurrent use with phosphodiesterase inhibitors
<b>Required Medical Information</b>	Diagnosis of covered use including WHO Group, submission of creatinine clearance (or serum creatinine, actual body weight, and height to calculate estimated creatinine clearance) and pregnancy status for female patients of childbearing potential. For pulmonary arterial hypertension (WHO Group 1), documentation diagnosis was confirmed by right heart catheterization.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to cardiology and pulmonology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## AKEEGA (niraparib/abiraterone)

---

### Products Affected

- AKEEGA

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment (Child-Pugh class C), uncontrolled hypertension, uncontrolled hypokalemia
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of deleterious BRCA mutation, baseline blood pressure reading, and serum potassium level, attestation patient will be using daily prednisone to match the indication and is using a gonadotropin-releasing hormone analog or has had a bilateral orchiectomy.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology and urology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ALECENSA (alectinib)

---

### Products Affected

- ALECENSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of ALK-positive tumor.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# ALPHA-1-PROTEINASE INHIBITORS

## Products Affected

- ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG, 500 MG
- GLASSIA
- PROLASTIN-C INTRAVENOUS SOLUTION
- ZEMAIRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Individuals with immunoglobulin A (IgA) deficiency who have known antibodies against IgA
<b>Required Medical Information</b>	Diagnosis of covered use, submission of pre-treatment alpha-1-antitrypsin (AAT) showing levels below 11 mmol/L (80 mg/dL), confirmation that patient has clinically evident emphysema secondary to congenital alpha-1-PI deficiency by submission of pulmonary function testing (e.g., spirometry or body plethysmography), X-ray radiography, or diffusing capacity of the lung for carbon monoxide (DLCO).
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to pulmonology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. Continuation of therapy requests require objective documentation from the prescriber that the patient's symptoms have improved. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# ALUNBRIG (brigatinib)

---

## Products Affected

- ALUNBRIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of ALK-positive tumor.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



# AMANTADINE EXTENDED-RELEASE PRODUCTS

---

## Products Affected

- OSMOLEX ER ORAL TABLET ER 24 HOUR THERAPY PACK
- OSMOLEX ER ORAL TABLET EXTENDED RELEASE 24 HOUR 129 MG, 193 MG

PA Criteria	Criteria Details
Exclusion Criteria	End stage renal disease (creatinine clearance below 15 mL/min)
Required Medical Information	Diagnosis of covered use, documentation patient tried and failed immediate-release amantadine.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to neurology
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## AMVUTTRA (vutrisiran)

### Products Affected

- AMVUTTRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Prior or scheduled liver transplant, New York Heart Association (NYHA) heart failure classification greater than 2
<b>Required Medical Information</b>	Diagnosis of covered use confirmed by (1) genetic testing including a mutation in the TTR gene and (2) signs and/or symptoms of polyneuropathy, including submission of baseline polyneuropathy disability (PND) score (required to be less than or equal to IIIb), submission of NYHA heart failure classification (required to be less than or equal to 2), previous medication(s) patient has tried and failed (at least one of either inotersen or patisiran).
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to neurology and specialists in genetic diseases
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. For approval, the patient must have tried and failed to have an adequate response to or had an intolerance to either inotersen or patisiran. Documentation of a positive response to therapy will be required for initial reauthorization after the first year. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

3/1/2024

PA Criteria	Criteria Details
Part B Prerequisite	No

3/1/2024

# ARCALYST (rilonacept)

---

## Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	Active or chronic infection, coadministration with TNF-blocking agents
Required Medical Information	Diagnosis of covered use, TB skin test result obtained within the past 12 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ARIKAYCE (amikacin inhalation)

---

### Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	Non-refractory Mycobacterium avium complex (MAC) lung disease
Required Medical Information	Diagnosis of covered use, submission of other therapies that have been tried and failed or cannot be used because of a contraindication. For refractory MAC lung disease, submission of sputum culture result.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to infectious diseases and pulmonology
Coverage Duration	1 year
Other Criteria	This medication is covered as a Part B benefit except for enrollees residing in a long-term care facility. PA applies to all when covered as a Part D benefit.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## AUGTYRO (repotrectinib)

---

### Products Affected

- AUGTYRO

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with moderate or strong CYP3A4 inhibitors or inducers, coadministration with P-glycoprotein inhibitors
Required Medical Information	Diagnosis of covered use, submission of test confirming tumor is ROS1-positive, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## AURYXIA (ferric citrate)

---

### Products Affected

- AURYXIA

PA Criteria	Criteria Details
Exclusion Criteria	Iron overload syndrome
Required Medical Information	Diagnosis of covered use.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## AUVELITY (dextromethorphan/bupropion)

---

### Products Affected

- AUVELITY

PA Criteria	Criteria Details
Exclusion Criteria	Seizure disorder, current or prior diagnosis of bulimia or anorexia nervosa, administration of monoamine oxidase inhibitors within 14 days of initiation
Required Medical Information	Diagnosis of covered use, prescription claims or documentation from physician showing patient has tried and failed or had an intolerance to at least two different medications that are indicated for the diagnosis.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



## AYVAKIT (avapritinib)

### Products Affected

- AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with moderate or strong CYP3A inducers or strong CYP3A inhibitors. For advanced or indolent systemic mastocytosis, platelet count below $50 \times 10^9/L$ .
Required Medical Information	Diagnosis of covered use, submission of pregnancy status for female patients of childbearing potential. For gastrointestinal stromal tumor (GIST), submission of test result confirming presence of PDGFRA exon 18 mutation. For advanced or indolent systemic mastocytosis, submission of platelet count.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to allergy, immunology, and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## BALVERSA (erdafitinib)

### Products Affected

- BALVERSA

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of susceptible FGFR3 genetic alterations, prior chemotherapy regimen(s) used (see Other Criteria), pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. This drug is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. Balversa will not be approved in PD-1/PD-L1 inhibitor-eligible patients who have not received this therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# BEMPEDOIC ACID

## Products Affected

- NEXLETOL
- NEXLIZET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant pravastatin utilization with doses above 40 mg/day, concomitant simvastatin utilization with doses above 20 mg/day
<b>Required Medical Information</b>	Diagnosis of covered use, submission of current or previous lipid-lowering therapies (see Other Criteria). For heterozygous familial hypercholesterolemia, documentation of genetic test result documenting HeFH or diagnosis by clinical criteria using Simon Broom or WHO/Dutch Lipid Network criteria. For atherosclerotic cardiovascular disease, "established" disease is defined as either (1) a documented history of coronary heart disease (CHD), to include at least one of the following: (a) prior myocardial infarction (MI, "heart attack"), (b) prior silent MI, (c) unstable angina, (d) prior coronary revascularization procedure, or (e) clinically significant CHD diagnosed by invasive or non-invasive testing, or (2) at least one CHD risk equivalent, to include (a) peripheral arterial disease, or (b) previous ischemic stroke with a focal ischemic neurological deficit that persisted more than 24 hours, considered as being of atherothrombotic origin.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only. For approval, the patient must currently be using a statin plus ezetimibe or the patient must have tried and failed to have an adequate response to or had an intolerance to at least two statins or one statin and ezetimibe. At least one statin previously tried and failed must be a hydrophilic statin.
<b>Indications</b>	All FDA-approved Indications.

3/1/2024

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# BENLYSTA (belimumab)

## Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Severe active central nervous system lupus, patients using other biologic medications or intravenous cyclophosphamide
Required Medical Information	Diagnosis of covered use, confirmation that the patient is taking standard therapy defined as at least one of the following: systemic corticosteroids (e.g., prednisone), antimalarials (e.g., hydroxychloroquine), or immunosuppressants (e.g., azathioprine, methotrexate, mycophenolate mofetil). For systemic lupus erythematosus, submission of autoantibody-positive test result for anti-nuclear antibodies (ANA) and/or anti-double-stranded DNA (anti-dsDNA).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## BESREMI (ropeginterferon alfa-2b-njft)

### Products Affected

- BESREMI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	History or presence of severe psychiatric disorders (including severe depression or suicidal ideation), history of presence of active serious or untreated autoimmune disease, moderate or severe hepatic impairment (Child-Pugh class B or C), immunosuppressed transplant recipients, severe or unstable cardiovascular disease (e.g., uncontrolled hypertension, NYHA class 2-4 congestive heart failure, serious cardiac arrhythmia, significant coronary artery stenosis, unstable angina), stroke or myocardial infarction within previous 6 months, severe renal impairment (eGFR less than 30 mL/min/1.73 m <sup>2</sup> )
<b>Required Medical Information</b>	Diagnosis of covered use, submission of eGFR, documentation patient has tried and failed, has a contraindication to, or could not tolerate hydroxyurea, pregnancy status for female patients of childbearing potential.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to hematology and oncology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# BEXAROTENE GEL

---

## Products Affected

- *bexarotene external*

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of covered use, submission of previous therapies.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to dermatology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# BIOLOGIC RESPONSE MODIFIERS

## Products Affected

- ACTEMRA ACTPEN
- ACTEMRA SUBCUTANEOUS
- CIMZIA STARTER KIT SUBCUTANEOUS PREFILLED SYRINGE KIT
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG
- CIMZIA SUBCUTANEOUS PREFILLED SYRINGE KIT
- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- OTEZLA
- SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- SOTYKTU
- TREMFYA
- VELSIPITY
- ZEPOSIA
- ZEPOSIA 7-DAY STARTER PACK
- ZEPOSIA STARTER KIT ORAL CAPSULE THERAPY PACK 0.23MG & 0.46MG 0.92MG(21)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For Zeposia for the treatment of multiple sclerosis, only diagnosis of covered use is required. For all other drugs managed by this policy and for Zeposia for indications other than multiple sclerosis, diagnosis of covered use, submission of previous therapies. For all drugs managed by this policy except Otezla, Velsipity, and Zeposia, submission of baseline latent tuberculosis screening test (Mantoux tuberculin skin test [a.k.a. PPD test] or interferon-gamma release assay [IGRA]).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year

3/1/2024



PA Criteria	Criteria Details
<b>Other Criteria</b>	PA applies to all. With the exception of Zeposia for the treatment of multiple sclerosis only, for approval of a drug managed by this policy, the patient must have tried and failed to have an adequate response to or had an intolerance to at least two preferred agents (Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, and Xeljanz/Xeljanz XR) for the indication submitted, where possible. For all drugs managed by this policy except Otezla, Velsipity, and Zeposia, if TB screening test returns a positive result, coverage will be delayed until latent TB is treated. For re-authorization, yearly TB screening test or chest X-ray required for patients who live in, work in, or travel to areas where TB exposure is likely while on treatment or for those who have previously had a positive TB screening test.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# BOSULIF (bosutinib)

## Products Affected

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coadministration with moderate or strong CYP3A inhibitors or strong CYP3A inducers
<b>Required Medical Information</b>	Diagnosis of covered use, submission of renal function testing, submission of pregnancy status for female patients of childbearing potential. For accelerated or blast phase Ph+ CML, documentation of resistance or intolerance to at least one of the following prior therapies: imatinib, dasatinib, or nilotinib.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Restricted to hematology and oncology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## BRAFTOVI/MEKTOVI (encorafenib/binimetinib)

### Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG
- MEKTOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of BRAF V600E or V600K mutation based on requirements for diagnosis. For metastatic melanoma or metastatic non-small cell lung cancer, confirmation that encorafenib and binimetinib will be co-administered. For metastatic colorectal cancer, confirmation that encorafenib and cetuximab will be co-administered.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## BRONCHITOL (mannitol powder for inhalation)

---

### Products Affected

- BRONCHITOL

PA Criteria	Criteria Details
Exclusion Criteria	Documented Bronchitol Tolerance Test failure
Required Medical Information	Diagnosis of covered use, documentation patient has passed the Bronchitol Tolerance Test.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to pulmonology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## BRUKINSA (zanubrutinib)

### Products Affected

- BRUKINSA

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of pregnancy status for female patients of childbearing potential. For mantle cell lymphoma or marginal zone lymphoma, submission of prior regimen(s) used.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# BUTALBITAL-CONTAINING PRODUCTS IN OLDER PATIENTS

## Products Affected

- ASCOMP-CODEINE 40 mg
- *butalbital-acetaminophen oral tablet 50-325 mg*
- *butalbital-apap-caff-cod*
- *butalbital-apap-caffeine oral capsule*
- *butalbital-apap-caffeine oral tablet 50-325-*
- *butalbital-asa-caff-codeine*
- *butalbital-aspirin-caffeine oral capsule*
- TENCON ORAL TABLET 50-325 MG
- ZEBUTAL ORAL CAPSULE 50-325-40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, documentation patient has tried and failed a preferred alternative such as ibuprofen or rizatriptan, or has contraindications to all alternatives.
Age Restrictions	PA applies to patients 65 years of age or older. PA does not apply to patients 64 years of age or younger.
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## BYLVAY (odevixibat)

---

### Products Affected

- BYLVAY
- BYLVAY (PELLETS)

PA Criteria	Criteria Details
Exclusion Criteria	History of liver transplant, clinical evidence of decompensated cirrhosis
Required Medical Information	Diagnosis of covered use confirmed by molecular genetic testing, attestation drug-induced pruritus has been ruled out.
Age Restrictions	
Prescriber Restrictions	Restricted to gastroenterology and hepatology
Coverage Duration	1 year
Other Criteria	PA applies to all. Attestation of improvement in pruritus symptoms and submission of liver function testing, including serum bilirubin, since the previous authorization will be required for subsequent reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## CABLIVI (caplacizumab-yhdp)

### Products Affected

- CABLIVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, confirmation drug will be given with plasma exchange and immunosuppressive therapy. If the coverage determination request is not for the patient's first use of caplacizumab, submission of previous aTTP recurrences while on caplacizumab.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to cardiology, hematology, and immunology
Coverage Duration	3 months
Other Criteria	PA applies to all. If the coverage determination request is not for the patient's first use of caplacizumab, coverage will not be authorized if the patient has had more than 2 recurrences of aTTP while on therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



## CABOMETYX (cabozantinib)

---

### Products Affected

- CABOMETYX

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment, uncontrolled hypertension
Required Medical Information	Diagnosis of covered use, submission of pregnancy status for female patients of childbearing potential. For hepatocellular carcinoma, confirmation patient was previously treated with sorafenib. For differentiated thyroid cancer, submission of previous therapy or therapies tried and failed.
Age Restrictions	12 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## CALQUENCE (acalabrutinib)

---

### Products Affected

- CALQUENCE

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment, coadministration with strong CYP3A inhibitors
Required Medical Information	Diagnosis of covered use, submission of pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# CAMZYOS (mavacamten)

## Products Affected

- CAMZYOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Left ventricular ejection fraction (LVEF) less than 55%, coadministration with a non-dihydropyridine (DHP) calcium channel blocker (CCB) plus disopyramide
<b>Required Medical Information</b>	Diagnosis of covered use including all three of the following: (1) attestation patient has exertional symptoms consistent with the definition of NYHA class II or III disease, (2) confirmation of left ventricular (LV) outflow tract obstruction gradient of at least 50 mmHg either at rest, during Valsalva maneuver testing, or after exercise, and (3) confirmation of LV wall thickness of at least 15 mm or at least 13 mm if condition is familial, submission of current LVEF, any previous or current therapies tried for the condition, pregnancy status for female patients of childbearing potential.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to cardiology
<b>Coverage Duration</b>	Initially 6 months, then 1 year
<b>Other Criteria</b>	PA applies to all. For approval, the patient must have tried and failed to have an adequate response to or had an intolerance/contraindication to both a beta-blocker and a non-DHP CCB. Documentation of a positive response to therapy will be required for initial reauthorization after the first 6 months. Maintenance of a clinical benefit and attestation that prescriber believes benefits of continuing therapy outweigh the potential risks to the patient will be required for subsequent annual reauthorizations.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

3/1/2024

PA Criteria	Criteria Details
Part B Prerequisite	No

3/1/2024

## CAPLYTA (lumateperone)

---

### Products Affected

- CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG

PA Criteria	Criteria Details
Exclusion Criteria	Dementia-related psychosis, coadministration with CYP3A4 inducers
Required Medical Information	Diagnosis of covered use. For schizophrenia, submission of previous therapies used (see Other Criteria).
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to psychiatry
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. For approval for schizophrenia, the patient must have tried and failed to have an adequate response to or had an intolerance to aripiprazole and at least one other generic second-generation atypical antipsychotic.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## CAPRELSA (vandetanib)

---

### Products Affected

- CAPRELSA

PA Criteria	Criteria Details
Exclusion Criteria	History of congenital long QT syndrome, torsades de pointes, uncompensated heart failure, or bradyarrhythmias, QTcF interval greater than 450 msec
Required Medical Information	Diagnosis of covered use, submission of baseline serum potassium, calcium, magnesium, creatinine clearance (or serum creatinine, actual body weight, and height to calculate estimated creatinine clearance), ECG, and pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# CARGLUMIC ACID

---

## Products Affected

- *carglumic acid oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of elevated plasma ammonia level.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. Updated plasma ammonia level since the previous authorization will be required for subsequent reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## CERDELGA (eliglustat)

---

### Products Affected

- CERDELGA

PA Criteria	Criteria Details
Exclusion Criteria	Pre-existing cardiac disease, long QT syndrome, coadministration with Class Ia or Class III antiarrhythmics
Required Medical Information	Diagnosis of covered use, submission of CYP2D6 metabolizer status as detected by a test for determining CYP2D6 genotype, liver function testing or Child-Pugh score.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. Updated liver function testing or Child-Pugh score since the previous authorization will be required for subsequent reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



# CGRP INHIBITORS

## Products Affected

- AIMOVIG SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140 MG/ML, 70 MG/ML
- AJOVY
- EMGALITY
- EMGALITY (300 MG DOSE)
- NURTEC
- QULIPTA
- UBRELVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use. For migraine headache prevention, submission of baseline headache days per month from medical chart, documentation patient (a) has tried and failed at least two non-CGRP inhibitor FDA-approved (propranolol, timolol, topiramate, valproic acid) or compendial alternatives (e.g., amitriptyline, atenolol) for migraine prophylaxis, or (b) has tried and failed at least one alternative from (a) if they have contraindications to all other alternatives, or (c) has contraindications to all alternatives from (a). For acute migraine treatment, documentation of prior use of at least one triptan.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	For migraine headache prevention, initially 3 months, then 1 year. For acute migraine, 1 year.
<b>Other Criteria</b>	PA applies to all. For episodic migraine prevention, the patient must have documentation of fewer than 15 headache days per month. For approval of Emgality for migraine headache prevention, the patient must have tried and failed to have an adequate response to or had an intolerance to Aimovig and Ajoyv. For migraine headache prevention reauthorization after the first 3 months, submission of on-treatment headache days per month demonstrating improvement from baseline will be required. Documentation of maintenance of a clinical benefit will be required for subsequent reauthorizations.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

3/1/2024

PA Criteria	Criteria Details
Part B Prerequisite	No

3/1/2024

## CHENODAL (chenodiol)

---

### Products Affected

- CHENODAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Pregnancy, known hepatocyte dysfunction, bile duct abnormalities such as intrahepatic cholestasis, primary biliary cirrhosis, or sclerosing cholangitis, radiopaque stones, nonvisualizing gallbladder confirmed as nonvisualizing after 2 consecutive single doses of dye, compelling reasons for gallbladder surgery
<b>Required Medical Information</b>	Diagnosis of covered use.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 months
<b>Other Criteria</b>	PA applies to all.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## CHOLBAM (cholic acid)

---

### Products Affected

- CHOLBAM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of liver function testing.
Age Restrictions	
Prescriber Restrictions	Restricted to hepatology, gastroenterology, and pediatric gastroenterology
Coverage Duration	Initially 3 months, then 1 year
Other Criteria	PA applies to all. Documentation of liver function improvement without complete biliary obstruction or persistent clinical or laboratory indications of worsening liver function or cholestasis will be required for initial reauthorization after the first 3 months. Updated liver function testing since the previous authorization will be required for subsequent reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## COMETRIQ (cabozantinib)

### Products Affected

- COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment (Child-Pugh class C)
Required Medical Information	Diagnosis of covered use, submission of pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# COPIKTRA (duvelisib)

## Products Affected

- COPIKTRA ORAL CAPSULE 15 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of at least two prior therapies tried and failed, submission of pregnancy status for female patients of childbearing potential, attestation patient will receive prophylaxis for Pneumocystis jirovecii pneumonia (PJP) and, if necessary, cytomegalovirus.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology or oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# CORTROPHIN (corticotropin)

## Products Affected

- CORTROPHIN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Request for IV administration, treatment of patients under 2 years of age in whom congenital infections are suspected, patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, a history of or presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin
<b>Required Medical Information</b>	Diagnosis of covered use, submission of blood pressure reading and baseline serum sodium and potassium levels.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. Updated blood pressure, sodium, and potassium levels since the previous authorization will be required for subsequent reauthorizations. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## COTELLIC/ZELBORAF (cobimetinib/vemurafenib)

### Products Affected

- COTELLIC
- ZELBORAF

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	For cobimetinib, coadministration with moderate or strong CYP3A inhibitors or inducers. For vemurafenib, electrolyte abnormalities that are not correctable.
<b>Required Medical Information</b>	Diagnosis of covered use including verification of BRAF V600 mutation as needed for diagnosis. For patients using cobimetinib, submission of left ventricular ejection fraction (LVEF) with a requirement the baseline LVEF is greater than or equal to 40%. For patients using vemurafenib, submission of QTc interval with a requirement the QT interval is less than or equal to 500 msec).
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to oncology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only. Vemurafenib is not indicated in wild-type BRAF melanoma and will not be approved for this use.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024



## CRESEMBA (isavuconazonium)

---

### Products Affected

- CRESEMBA ORAL CAPSULE 186 MG

PA Criteria	Criteria Details
Exclusion Criteria	Familial short QT syndrome, coadministration with strong CYP3A inhibitors or inducers
Required Medical Information	Diagnosis of covered use.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology, infectious diseases, and oncology.
Coverage Duration	6 months
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# CYSTEAMINE EYE DROPS

---

## Products Affected

- CYSTADROPS
- CYSTARAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, confirmation of corneal cysteine crystal deposits as seen on slit-lamp examination.
Age Restrictions	
Prescriber Restrictions	Restricted to metabolic diseases specialty, optometry, and ophthalmology
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# DALFAMPRIDINE

## Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
Exclusion Criteria	History of seizure, moderate or severe renal impairment (CrCl less than or equal to 50 mL/min)
Required Medical Information	Diagnosis of covered use, submission of creatinine clearance (or serum creatinine, actual body weight, and height to calculate estimated creatinine clearance), confirmation that patient is able to walk.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to neurology
Coverage Duration	1 year
Other Criteria	PA applies to all. Updated creatinine clearance since the previous authorization and confirmation patient is able to walk will be required for subsequent annual reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## DAURISMO (glasdegib)

---

### Products Affected

- DAURISMO ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, confirmation patient will also be receiving cytarabine as part of chemotherapeutic regimen. If patient is under 75 years of age, documentation of comorbidities that preclude use of intensive induction chemotherapy, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# DEFERASIROX

## Products Affected

- *deferasirox oral tablet*
- *deferasirox oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment, estimated glomerular filtration rate less than 40 mL per min, platelet count below $50 \times 10^9/L$ , high-risk myelodysplastic syndromes, advanced malignancies
Required Medical Information	Diagnosis of covered use, submission of CBC, LFTs, ferritin, and urine protein values, estimated glomerular filtration rate, documentation that member has had yearly ophthalmic and auditory testing.
Age Restrictions	2 years of age or older
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	PA applies to all. Updated ferritin level within last 3 months and updated CBC, LFT, urine protein value, estimated glomerular filtration rate, and ophthalmic and auditory testing since the previous authorization (within previous year) will be required for subsequent reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# DEFERIPRONE

## Products Affected

- *deferiprone*
- FERRIPROX ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	Absolute neutrophil count (ANC) below $1.5 \times 10^9/L$
Required Medical Information	Diagnosis of covered use, submission of serum ferritin levels, ANC, pregnancy status for female patients of childbearing potential.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. Updated ferritin level and ANC within last 3 months will be required for subsequent reauthorizations. Safety and effectiveness have not been established for transfusional iron overload in patients with myelodysplastic syndrome or Diamond Blackfan anemia and will not be approved for these indications.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## DIACOMIT (stiripentol)

---

### Products Affected

- DIACOMIT

PA Criteria	Criteria Details
Exclusion Criteria	Moderate or severe renal impairment, moderate or severe hepatic impairment
Required Medical Information	Diagnosis of covered use, confirmation patient is also receiving clobazam.
Age Restrictions	
Prescriber Restrictions	Restricted to neurology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. Monotherapy requests for Dravet syndrome will not be approved as there are no clinical data to support using stiripentol in this manner.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# DICHLORPHENAMIDE

## Products Affected

- *dichlorphenamide*
- KEVEYIS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use of high dose aspirin, severe pulmonary disease limiting compensation to metabolic acidosis, hepatic insufficiency
<b>Required Medical Information</b>	Diagnosis of covered use.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initially 2 months, then 1 year
<b>Other Criteria</b>	PA applies to all. Documentation of a positive response to therapy will be required for initial reauthorization after the first 2 months. Maintenance of a clinical benefit will be required for subsequent annual reauthorizations.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024



# DICLOFENAC PATCH

## Products Affected

- *diclofenac epolamine external*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery, use on non-intact or damaged skin resulting from any etiology including exudative dermatitis, eczema, infection lesions, burns, or wounds, pregnancy after 30 weeks gestation
<b>Required Medical Information</b>	Diagnosis of covered use.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	PA applies to all. Product is approved for acute pain, defined as short-term pain not lasting longer than a 3-month period.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# DIGOXIN IN OLDER PATIENTS

## Products Affected

- *digoxin oral tablet 250 mcg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use, submission of creatinine clearance (or serum creatinine, actual body weight, and height to calculate estimated creatinine clearance) with result greater than or equal to 30 mL/min. Patient must have tried and failed to respond adequately to 0.125 mg of digoxin.
<b>Age Restrictions</b>	PA applies to patients 65 years of age or older. PA does not apply to patients 64 years of age or younger.
<b>Prescriber Restrictions</b>	PA not required for cardiology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all except cardiology. PA not required for doses less than or equal to 0.125 mg per day. Updated creatinine clearance since the previous authorization will be required for subsequent annual reauthorizations.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# DOPTELET (avatrombopag)

## Products Affected

- DOPTELET ORAL TABLET 20 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use. For immune thrombocytopenia (ITP), submission of platelet count with a requirement it is less than $30 \times 10^9/L$ or less than $50 \times 10^9/L$ with documented increased risk of bleeding, documentation patient has undergone splenectomy and/or tried and failed two different ITP therapies including systemic corticosteroids, immunoglobulins, danazol, fostamatinib, or cytotoxics/immunosuppressants such as rituximab.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to gastroenterology, hematology, hepatology, and surgery
Coverage Duration	For patients undergoing a procedure, 5 days. For ITP, initially 6 months, then 1 year.
Other Criteria	PA applies to all. For ITP, documentation of an improvement in platelet count will be required for initial reauthorization after the first 6 months. Maintenance of a clinical benefit will be required for subsequent annual reauthorizations. This medication should not be administered to patients with chronic liver disease not scheduled to undergo a procedure in an attempt to normalize platelet counts and will not be approved for this indication.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# DRONABINOL

## Products Affected

- *dronabinol*
- SYNDROS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use. If authorization is requested for treatment of nausea and vomiting associated with cancer therapy, documentation of previous conventional antiemetic therapies utilized is required.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. If authorization is requested for treatment of nausea and vomiting associated with cancer therapy, the patient must have tried and failed to have an adequate response to at least one 5-HT3 receptor antagonist (e.g., granisetron, ondansetron). If the medication is being administered related to cancer treatment and is a full replacement for intravenous administration of antiemetic therapy within 48 hours of cancer treatment, it is covered as a Part B benefit. To be eligible for Part B coverage, the prescribing physician must indicate this on the prescription. If the medication is being requested for the use of anorexia associated with weight loss in patients with AIDS, approval may be covered under Part D.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## DUOBRII (halobetasol/tazarotene)

### Products Affected

- DUOBRII

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of covered use, pregnancy status for female patients of childbearing potential, documentation patient tried and failed augmented betamethasone dipropionate, clobetasol, fluocinonide 0.1%, halobetasol, or another Class I ultra-high potency topical steroid.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to dermatology
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# DUPIXENT (dupilumab)

## Products Affected

- DUPIXENT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use. For atopic dermatitis, (1) documentation of at least 10% body surface area involvement, and (2) documentation of treatment with at least a moderate strength topical corticosteroid for at least four weeks, a contraindication to the use of topical corticosteroids, or documentation why this therapy is not otherwise advisable. For moderate-to-severe asthma, (1) documentation patient has a pre-bronchodilator FEV1 less than 80 percent predicted, (2) submission of either blood eosinophil count of at least 150 cells/mcL obtained within 6 weeks of therapy initiation or documentation asthma requires daily oral corticosteroid for control, and (3) attestation dupilumab will be used in addition to other chronic therapies. For chronic rhinosinusitis with nasal polyposis, (1) documentation of treatment with an intranasal corticosteroid for at least three months, a contraindication to the use of intranasal corticosteroids, or why therapy is not otherwise advisable, and (2) if the patient does not have an intolerance or contraindication to intranasal corticosteroids, attestation dupilumab will be used in addition to this therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Restricted to allergy, dermatology, gastroenterology, immunology, otolaryngology/otorhinolaryngology, and pulmonology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. Continuation requires documentation of a positive response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

3/1/2024

PA Criteria	Criteria Details
Part B Prerequisite	No

3/1/2024

## EGRIFTA SV (tesamorelin)

### Products Affected

- EGRIFTA SV

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy, active malignancy, disruption of HPA axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation, or head trauma
Required Medical Information	Diagnosis of covered use, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. Continuation of therapy requests require confirmation that the patient has demonstrated a clinical improvement (or maintenance of improvement once achieved) from baseline. Tesamorelin is not indicated for weight loss management and will not be approved for this indication.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



## ENDARI (L-glutamine)

---

### Products Affected

- ENDARI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of sickle cell disease
Age Restrictions	
Prescriber Restrictions	Restricted to hematology
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# ENDOTHELIN RECEPTOR ANTAGONISTS

## Products Affected

- *ambrisentan oral tablet 10 mg, 5 mg*
- *bosentan oral tablet 125 mg, 62.5 mg*
- OPSUMIT
- TRACLEER ORAL TABLET SOLUBLE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Pregnancy. For ambrisentan, idiopathic pulmonary fibrosis and moderate or severe hepatic impairment.
<b>Required Medical Information</b>	Diagnosis of covered use, submission of pregnancy status for female patients of childbearing potential. For Opsumit, documentation of previous endothelin receptor antagonists tried and reason patient can no longer use them.
<b>Age Restrictions</b>	For ambrisentan and Opsumit, 18 years of age or older. For bosentan, 3 years of age or older.
<b>Prescriber Restrictions</b>	Restricted to cardiology and pulmonology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only. For approval of Opsumit, the patient must have tried and failed to have an adequate response to or had an intolerance or contraindication to both ambrisentan and bosentan.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# ENSPRYNG (satralizumab-mwge)

## Products Affected

- ENSPRYNG

PA Criteria	Criteria Details
Exclusion Criteria	Active hepatitis B infection, active or untreated latent tuberculosis (TB)
Required Medical Information	Diagnosis of covered use, submission of confirmation patient has anti-aquaporin-4 (AQP4) antibody-positive NMOSD, submission of baseline latent TB screening test (Mantoux tuberculin skin test [a.k.a. PPD test] or interferon-gamma release assay [IGRA]), attestation patient does not have any active infection.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to neurology and ophthalmology
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## EPIDIOLEX (cannabidiol)

---

### Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use.
Age Restrictions	1 year of age or older
Prescriber Restrictions	Restricted to neurology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ERIVEDGE (vismodegib)

---

### Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of covered use, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# ERLOTINIB

## Products Affected

- *erlotinib hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use. For non-small cell lung cancer, submission of test confirming presence of EGFR exon 19 deletion or exon 21 L858R substitution mutation and prior treatments used.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# ERYTHROPOIETINS

## Products Affected

- ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML
- ARANESP (ALBUMIN FREE) INJECTION SOLUTION PREFILLED SYRINGE
- RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of hemoglobin level less than 10 g/dL (at initial submission for non-surgery indications only), attestation serum iron, total iron-binding capacity (TIBC), and transferrin saturation level have been assessed within 30 days of request date, documentation that the patient does not have uncontrolled hypertension.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	For non-ESRD-related conditions: 90 days. For ESRD-related conditions: 1 year.
Other Criteria	PA applies to all. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# EVEROLIMUS

## Products Affected

- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus oral tablet soluble*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coadministration with dual strong CYP3A4/P-glycoprotein inhibitors
<b>Required Medical Information</b>	Diagnosis of covered use and submission of pregnancy status for female patients of childbearing potential. For renal cell carcinoma, documented prior use of sunitinib or sorafenib. For postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer, documentation of treatment failure with letrozole or anastrozole and confirmation drug is being used in combination with exemestane.
<b>Age Restrictions</b>	1 year of age or older
<b>Prescriber Restrictions</b>	Restricted to neurology and oncology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024



## EVRYSDI (risdiplam)

### Products Affected

- EVRYSDI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use confirmed by genetic testing including either (a) homozygous deletion of SMN1 exon 7 or (b) compound heterozygosity for SMN1 exon 7 deletion and small mutation, documentation of two or more copies of the SMN2 gene by genetic testing, submission of pregnancy status for female patients of childbearing potential.
Age Restrictions	
Prescriber Restrictions	Restricted to neurology
Coverage Duration	Initially 6 months, then 1 year
Other Criteria	PA applies to all. Maintenance of or improvement in any motor score or function compared to baseline will be required for reauthorization.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## EXKIVITY (mobocertinib)

### Products Affected

- EXKIVITY

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with moderate or strong CYP3A4 inducers, coadministration with strong CYP3A4 inhibitors
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of EGFR exon 20 insertion mutation and previous therapies used, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. For approval, the patient must have documentation of failure of or contraindication to platinum-based chemotherapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# FENTANYL TRANSMUCOSAL

## Products Affected

- *fentanyl citrate buccal*

PA Criteria	Criteria Details
Exclusion Criteria	Patients not tolerant to the effects of a chronic opioid, treatment of acute or postoperative pain including headache, migraines, or dental pain
Required Medical Information	Diagnosis of covered use with the requirement transmucosal fentanyl will only be used for the treatment of breakthrough cancer pain, verified claim or documentation of patient's morphine milligram equivalent opioid dose.
Age Restrictions	For the buccal tablet, 18 years of age or older. For the lozenge, 16 years of age or older.
Prescriber Restrictions	PA not required for oncology
Coverage Duration	1 year
Other Criteria	PA applies to all except oncology. Transmucosal fentanyl is only covered as a Part D drug for the treatment of breakthrough cancer pain and will not be authorized for other uses.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# FILGRASTIM

## Products Affected

- NEUPOGEN INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6ML
- NEUPOGEN INJECTION SOLUTION PREFILLED SYRINGE
- NIVESTYM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	For approval of Nivestym for any indication or of Neupogen for any indication other than Hematopoietic Syndrome of Acute Radiation Syndrome, the patient must have tried and failed to have an adequate response to or had an intolerance to Zarxio. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## FILSPARI (sparsentan)

### Products Affected

- FILSPARI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Pregnancy, hepatic impairment, coadministration with renin-angiotensin system antagonists or endothelin receptor antagonists
<b>Required Medical Information</b>	Diagnosis of primary IgA nephropathy confirmed by biopsy, submission of 24-hour urine protein of at least 1 g/day or 24-hour urine protein-to-creatinine ratio of at least 0.8 g/g, eGFR, and liver function testing or Child-Pugh class, pregnancy status for female patients of childbearing potential, attestation patient is stable on a maximally-tolerated ACE inhibitor or ARB and will discontinue this drug upon receiving sparsentan, documentation patient has progressed on at least one immunosuppressant (e.g., azathioprine, mycophenolate, etc.).
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to immunology and nephrology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. Reauthorization requires documentation of clinically relevant response to therapy, including, but not limited to stabilization or improvement of urine protein-to-creatinine ratio or eGFR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## FINTEPLA (fenfluramine)

### Products Affected

- FINTEPLA

PA Criteria	Criteria Details
Exclusion Criteria	Administration of monoamine oxidase inhibitors within 14 days of initiation
Required Medical Information	Diagnosis of covered use, submission of creatinine clearance (or serum creatinine, actual body weight, and height to calculate estimated creatinine clearance) and liver function testing or Child-Pugh score.
Age Restrictions	2 years of age or older
Prescriber Restrictions	Restricted to neurology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## FIRDAPSE (amifampridine)

---

### Products Affected

- FIRDAPSE

PA Criteria	Criteria Details
Exclusion Criteria	History of seizure
Required Medical Information	Diagnosis of covered use confirmed by either electromyography or calcium channel antibody testing.
Age Restrictions	6 years of age or older
Prescriber Restrictions	Restricted to neurology
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# FIRST-GENERATION ANTIHISTAMINES IN OLDER PATIENTS

## Products Affected

- *carbinoxamine maleate oral solution*
- *carbinoxamine maleate oral tablet 4 mg*
- *clemastine fumarate oral tablet 2.68 mg*
- *cyproheptadine hcl oral*
- *diphenhydramine hcl oral elixir*
- *hydroxyzine hcl oral tablet*
- *hydroxyzine pamoate oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use. For carbinoxamine or cyproheptadine for dermatographism, documentation patient tried and had an inadequate response to a second-generation antihistamine. For hydroxyzine for pruritus, documentation patient tried and had an inadequate response to a second-generation antihistamine. For hydroxyzine for anxiety, documentation patient has tried and had an inadequate response to at least 2 other FDA-approved products for the management of anxiety OR documentation medication is being used as a sedative before and after general anesthesia.
<b>Age Restrictions</b>	PA applies to patients 65 years of age or older. PA does not apply to patients 64 years of age or younger.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. First-generation antihistamines are anticholinergic medications considered high-risk in older patients due to risks of confusion, dry mouth, constipation, and decreased clearance with advanced age.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024



## FOTIVDA (tivozanib)

### Products Affected

- FOTIVDA

PA Criteria	Criteria Details
Exclusion Criteria	Uncontrolled hypertension, severe hepatic impairment, coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of previous systemic therapies used to treat renal cell carcinoma including the failure of at least one prior VEGFR inhibitor, pregnancy status for female patients of childbearing potential, confirmation patient has not had episodes of symptomatic heart failure or unstable angina, a myocardial infarction, an arterial thrombotic event, or a significant bleeding event in the 6 months preceding the prior authorization request.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## FRUZAQLA (fruquintinib)

---

### Products Affected

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment, uncontrolled hypertension, coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of baseline blood pressure reading, liver function testing or Child-Pugh score, and pregnancy status for female patients of childbearing potential, documentation of any clinically significant cardiovascular disease or thromboembolic events and, if there is a positive history, prescriber attestation benefit to patient outweighs potential risk of thromboembolic event.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# FUMARATES FOR MULTIPLE SCLEROSIS

## Products Affected

- BAFIERTAM
- VUMERITY

PA Criteria	Criteria Details
Exclusion Criteria	Hypersensitivity to dimethyl fumarate, coadministration with another fumarate. For Vumerity, moderate or severe renal impairment.
Required Medical Information	Diagnosis of covered use. For Vumerity, submission of creatinine clearance (or serum creatinine, actual body weight, and height to calculate estimated creatinine clearance).
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to neurology
Coverage Duration	1 year
Other Criteria	PA applies to all. For approval of Bafiertam or Vumerity, the patient must have tried and failed to have an adequate response to or had an intolerance to dimethyl fumarate. Updated creatinine clearance since the previous authorization will be required for subsequent annual reauthorizations of Vumerity.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## GALAFOLD (migalastat)

### Products Affected

- GALAFOLD

PA Criteria	Criteria Details
Exclusion Criteria	Severe renal impairment (eGFR less than 30 mL/min/1.73 m2) or end-stage renal disease requiring dialysis
Required Medical Information	Diagnosis of covered use, documentation that the patient has an amenable galactosidase alpha gene variant (see section 12.1, table 2 of package insert for full list) based on in vitro assay data as interpreted by a clinical genetics professional.
Age Restrictions	16 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# GATTEX (teduglutide)

## Products Affected

- GATTEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use including confirmation of dependency on parenteral nutrition at least 3 times per week. For adults 18 years of age or older only, submission of documentation that a colonoscopy (or alternate imaging) of the entire colon with polyp removal was performed within 6 months prior to starting treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. For adults 18 years of age or older, continuation of therapy requires submission of findings from a follow-up colonoscopy or alternate imaging result at the end of 1 year of teduglutide treatment. Subsequent imaging should be performed every 5 years, or sooner if polyps are found at the 1-year mark.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## GAVRETO (pralsetinib)

### Products Affected

- GAVRETO

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A4 inhibitors
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of RET gene fusion or mutation, attestation patient does not have uncontrolled hypertension, pregnancy status for female patients of childbearing potential.
Age Restrictions	12 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# GEFITINIB

## Products Affected

- *gefitinib*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, submission of pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## GILOTRIF (afatinib)

### Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use. For non-small cell lung cancer, submission of test confirming presence of non-resistant epidermal growth factor receptor mutations. For metastatic squamous non-small cell lung cancer, documentation of progression after platinum-based chemotherapy.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



# GROWTH HORMONE

## Products Affected

- NORDITROPIN FLEXPON SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 10 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 20 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 5 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- SOGROYA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, documentation of growth failure, submission of IGF-1 levels, height, weight, creatinine clearance (or serum creatinine), fasting blood glucose, and bone age if applicable based on patient age and diagnosis.
Age Restrictions	
Prescriber Restrictions	Restricted to endocrinology and nephrology
Coverage Duration	1 year
Other Criteria	PA applies to all. Updated IGF-1 level, bone age (if applicable based on patient age and diagnosis) height, weight, creatinine clearance (or serum creatinine), and fasting glucose since the previous authorization will be required for subsequent annual reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## HEREDITARY ANGIOEDEMA THERAPIES, ACUTE

### Products Affected

- BERINERT
- *icatibant acetate subcutaneous solution prefilled syringe*
- RUCONEST
- *sajazir subcutaneous solution prefilled syringe*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Requests for prophylactic hereditary angioedema therapy. For Ruconest, acute laryngeal attacks.
<b>Required Medical Information</b>	Diagnosis of covered use. For Ruconest, documentation of the patient's typical attack presentation/symptoms.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Restricted to allergy, dermatology, hematology, or immunology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# HEREDITARY ANGIOEDEMA THERAPIES, MAINTENANCE

## Products Affected

- HAEGARDA
- ORLADEYO
- TAKHZYRO SUBCUTANEOUS SOLUTION
- TAKHZYRO SUBCUTANEOUS SOLUTION

PREFILLED SYRINGE 300 MG/2ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Requests for acute hereditary angioedema therapy (attacks). For Orladeyo, end-stage renal disease.
<b>Required Medical Information</b>	Diagnosis of covered use, submission of objective or subjective documentation that prophylactic therapy is medically necessary, including, but not limited to activity of disease and disease burden, the frequency of HAE attacks, and quality of life.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Restricted to allergy, dermatology, hematology, or immunology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only. For approval of either Haegarda or Orladeyo for patients 12 years of age and older, the patient must have tried and failed to have an adequate response to or had an intolerance or contraindication to Takhzyro. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# IBRANCE (palbociclib)

## Products Affected

- IBRANCE

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use, submission of genetic tumor testing confirming primary tumor type is HR-positive, HER2-negative, confirmation that the treatment regimen will include concomitant use of an aromatase inhibitor or fulvestrant, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ICLUSIG (ponatinib)

### Products Affected

- ICLUSIG

PA Criteria	Criteria Details
Exclusion Criteria	Newly diagnosed chronic phase CML
Required Medical Information	Diagnosis of covered use, submission of pregnancy status for female patients of childbearing potential. For chronic phase CML that is not T315I-positive, documentation of resistance or intolerance to at least two prior kinase inhibitors.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## IDHIFA (enasidenib)

---

### Products Affected

- IDHIFA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of IDH2 mutation, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# IMBRUVICA (ibrutinib)

## Products Affected

- IMBRUVICA

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment (Child-Pugh class C), coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, pregnancy status for female patients of childbearing potential. For chronic graft versus host disease, documentation of treatment failure with any other systemic immunosuppressive agent.
Age Restrictions	
Prescriber Restrictions	Restricted to hematology, oncology, and transplant specialty
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# IMMUNE GLOBULIN

## Products Affected

- BIVIGAM INTRAVENOUS SOLUTION 5 GM/50ML
- CUVITRU
- FLEBOGAMMA DIF
- GAMMAGARD
- GAMMAGARD S/D LESS IGA
- GAMMAKED INJECTION SOLUTION 1 GM/10ML, 10 GM/100ML, 20 GM/200ML, 5 GM/50ML
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 20 GM/400ML, 5 GM/100ML, 5 GM/50ML
- GAMUNEX-C
- HIZENTRA SUBCUTANEOUS SOLUTION 1 GM/5ML, 10 GM/50ML, 2 GM/10ML, 4 GM/20ML
- HIZENTRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 10 GM/100ML, 10 GM/200ML, 2 GM/20ML, 2.5 GM/50ML, 20 GM/200ML, 5 GM/100ML, 5 GM/50ML
- PRIVIGEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.
<b>Required Medical Information</b>	Diagnosis of covered use. For ITP, submission of platelet count. For CLL, documentation of IgG level less than 600 mg/dL and recent history of serious bacterial infection requiring either oral or IV antibiotic therapy. For CIDP, unequivocal diagnosis and documentation patient is refractory, intolerant, or has a contraindication to systemic corticosteroids at therapeutic doses over at least 3 months. For passive immunization against varicella, confirmation that the patient is immunosuppressed and cannot receive varicella-zoster immune globulin.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	For acute conditions/new starts, 3 months. For renewal of chronic conditions, 1 year.

3/1/2024



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	PA applies to all. For continuation of any diagnosis, documentation of the clinical response to therapy must be submitted. For IV formulations, covered as a Part B benefit if administered in the home for the treatment of primary immune deficiency. For any other combination of treatment site and indication, additional information may need to be submitted to determine if the immune globulin will be covered as a Part B or Part D benefit.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# INLYTA (axitinib)

## Products Affected

- INLYTA

PA Criteria	Criteria Details
Exclusion Criteria	Uncontrolled hypertension, evidence of untreated brain metastasis, recent active gastrointestinal bleeding, coadministration with strong CYP3A4/5 inducers
Required Medical Information	Diagnosis of covered use, attestation patient does not have uncontrolled hypertension. If axitinib is being used as a single agent, submission of prior therapy or therapies tried and failed.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## INQOVI (decitabine/cedazuridine)

---

### Products Affected

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## INREBIC (fedratinib)

### Products Affected

- INREBIC

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment, thiamine deficiency, coadministration with moderate or strong CYP3A4 inducers or dual CYP3A4/CYP2C19 inhibitors
Required Medical Information	Diagnosis of covered use, submission of thiamine level and baseline platelet count, submission of all prior therapies used.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. For approval, the patient must have tried and failed to have an adequate response to or had an intolerance to ruxolitinib.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# INTRANASAL SEIZURE MEDICATIONS

## Products Affected

- NAYZILAM
- VALTOCO 10 MG DOSE
- VALTOCO 15 MG DOSE
- VALTOCO 20 MG DOSE
- VALTOCO 5 MG DOSE

PA Criteria	Criteria Details
Exclusion Criteria	Acute narrow-angle glaucoma
Required Medical Information	Diagnosis of covered use.
Age Restrictions	
Prescriber Restrictions	PA not required for neurology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# INVEGA INJECTABLE (paliperidone injectable suspension)

## Products Affected

- INVEGA HAFYERA MG/1.75ML, 819 MG/2.63ML
- INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML, 410 MG/1.32ML, 546

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Dementia-related psychosis
<b>Required Medical Information</b>	Diagnosis of covered use. For the 3-month injection, documentation of at least 4 months' treatment with 1-month paliperidone palmitate extended-release injectable suspension. For the 6-month injection, documentation of at least 4 months' treatment with 1-month paliperidone palmitate extended-release injectable suspension or at least one 3-month injection of 3-month paliperidone palmitate extended-release injectable suspension.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# ISTURISA (osilodrostat)

## Products Affected

- ISTURISA

PA Criteria	Criteria Details
Exclusion Criteria	Uncorrected hypokalemia or hypomagnesemia
Required Medical Information	Diagnosis of covered use, submission of 24-hour urine free cortisol (UFC) level demonstrating a baseline value more than 1.5 times the upper limit of normal (50 micrograms or 145 nmol), attestation pituitary gland surgery is not an option for the patient or has not been curative, submission of baseline serum potassium and magnesium levels.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to endocrinology
Coverage Duration	Initially 6 months, then 1 year
Other Criteria	PA applies to all. Continuation requires documentation of clinically relevant response to therapy, including, but not limited to 24-hour UFC level.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# IWILFIN (eflornithine)

## Products Affected

- IWILFIN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, documentation patient demonstrated at least a partial response to prior multiagent, multimodal therapy including an anti-GD2 immunotherapy, submission of pregnancy status for female patients of childbearing potential.
Age Restrictions	
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



## JAKAFI (ruxolitinib)

### Products Affected

- JAKAFI

PA Criteria	Criteria Details
Exclusion Criteria	Platelet count less than $50 \times 10^9/L$
Required Medical Information	Diagnosis of covered use, submission of baseline platelet count. For polycythemia vera, documented intolerance or inadequate response to hydroxyurea. For acute graft-versus-host disease, documented inadequate response to systemic corticosteroids. For chronic graft-versus-host-disease, documented failure of at least one previous line of systemic therapy.
Age Restrictions	
Prescriber Restrictions	Restricted to hematology, oncology, and transplant specialty
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## JAYPIRCA (pirtobrutinib)

### Products Affected

- JAYPIRCA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, documentation patient has tried and failed at least two previous lines of systemic therapy (see Other Criteria), pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. For mantle cell lymphoma, one of two previous lines of therapy must have included a Bruton's tyrosine kinase (BTK) inhibitor. For chronic lymphocytic leukemia or small lymphocytic lymphoma, previous lines of therapy must have included a Bruton's tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## JOENJA (leniolisib)

### Products Affected

- JOENJA

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy, moderate or severe hepatic impairment (Child-Pugh class B or C)
Required Medical Information	Diagnosis of covered use including submission of test confirming presence of a pathogenic variant of either PIK3CD or PIK3R1, submission of liver function testing or Child-Pugh score, confirmation of negative pregnancy status for female patients of childbearing potential or attestation from physician patient is not pregnant and will be using a highly effective method of contraception, attestation patient is not currently using an immunosuppressive medication.
Age Restrictions	12 years of age or older
Prescriber Restrictions	Restricted to specialists in genetic diseases or inborn errors of metabolism
Coverage Duration	Initially 6 months, then 1 year
Other Criteria	PA applies to all. Submission of objective documentation of a clinical benefit (e.g., normalization of lymphocyte subsets, normalization of lymphadenopathy, reduction in spleen size, etc.) in the absence of unacceptable toxicity will be required for subsequent reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# JUXTAPID (lomitapide)

## Products Affected

- JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Pregnancy, moderate or severe hepatic impairment (Child-Pugh class B or C), active liver disease, coadministration with moderate or strong CYP3A4 inhibitors
<b>Required Medical Information</b>	Diagnosis of covered use, including at least one of the following criteria: (1) documented functional mutation(s) in both LDL receptor alleles or alleles known to affect LDL receptor functionality, (2) skin fibroblast LDL receptor activity less than 20% of normal, or (3) untreated total cholesterol above 500 mg/dL and triglycerides less than 300 mg/dL and both parents with a documented untreated total cholesterol above 250 mg/dL, submission of baseline lab values including ALT, AST, alkaline phosphatase, total bilirubin, baseline LDL-C, total cholesterol (TC), apoB, and non-HDL-C, pregnancy status for female patients of childbearing potential, documentation of contraindication to or treatment failure with evolocumab.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to cardiology, lipidology, and endocrinology with experience in and a focus on lipid management
<b>Coverage Duration</b>	Initially 6 months, then 1 year
<b>Other Criteria</b>	PA applies to all. Submission of LDL level drawn after the initial LDL level submission documenting clinically significant response to therapy will be required for reauthorization. For approval, the patient must have tried and failed to have an adequate response to, had an intolerance to, or have a contraindication to therapy with evolocumab. There is no evidence for effectiveness in heterozygous familial hypercholesterolemia and will not be approved for this indication.
<b>Indications</b>	All Medically-accepted Indications.

3/1/2024

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## JYNARQUE (tolvaptan)

### Products Affected

- JYNARQUE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	History of signs or symptoms of significant liver impairment or injury (not including uncomplicated polycystic liver disease), uncorrected abnormal blood sodium concentrations, inability to sense or respond to thirst, hypovolemia, uncorrected urinary outflow obstruction, anuria, coadministration with strong CYP3A inhibitors or inducers or desmopressin
<b>Required Medical Information</b>	Diagnosis of covered use where "rapidly progressing" autosomal dominant polycystic kidney disease is defined as (1) total kidney volume increases of at least 5% per year confirmed by repeat MRI or ultrasound measurements at least 6 months apart or (2) GFR decline of at least 2.5 mL/min/year over a 5-year period or (3) GFR decline of at least 5 mL/min/year over the previous year, submission of serum sodium concentration.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to nephrology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## KALYDECO (ivacaftor)

---

### Products Affected

- KALYDECO

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of cystic fibrosis mutation test confirming presence of a CFTR gene mutation predicted to be responsive to ivacaftor (see section 12.1 of package insert for full list).
Age Restrictions	
Prescriber Restrictions	Restricted to pulmonology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## KERENDIA (finerenone)

### Products Affected

- KERENDIA

PA Criteria	Criteria Details
Exclusion Criteria	Adrenal insufficiency, estimated glomerular filtration rate (eGFR) less than 25 mL/min/1.73 m <sup>2</sup> , serum potassium above 5.0 mEq/L, severe (Child-Pugh class C) hepatic impairment, coadministration with strong CYP3A4 inhibitors or moderate or strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use, submission of estimated glomerular filtration rate (eGFR) and baseline serum potassium level.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. For approval, the patient must have documentation of a trial of Farxiga.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



# KETOCONAZOLE ORAL

---

## Products Affected

- *ketoconazole oral*

PA Criteria	Criteria Details
Exclusion Criteria	Acute or chronic liver disease, treatment of fungal meningitis or fungal infections of the skin or nails
Required Medical Information	Ketoconazole is being requested for the treatment of culture-proven systemic blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, or paracoccidioidomycosis, submission of baseline ALT, AST, total bilirubin, alkaline phosphatase, prothrombin time and INR, confirmation from the prescriber that the potential benefits of therapy outweigh the risks.
Age Restrictions	2 years of age or older
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# KISQALI (ribociclib)

## Products Affected

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Congenital long QT syndrome, QTcF interval greater than 450 msec at treatment initiation, uncorrected hypokalemia or hypomagnesemia, coadministration with strong CYP3A4 inducers or drugs that can prolong the QT interval
<b>Required Medical Information</b>	Diagnosis of covered use, submission of genetic tumor testing confirming the primary tumor type is HR-positive and HER2-negative, submission of QTcF interval, serum potassium and magnesium within the previous 6 months, and pregnancy status for female patients of childbearing potential. For patients receiving Kisqali alone, confirmation that the treatment regimen will include concomitant use of an aromatase inhibitor or fulvestrant.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to oncology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# KORLYM (mifepristone)

## Products Affected

- KORLYM
- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Pregnancy, severe hepatic impairment, uncorrected hypokalemia, female patients with a history of unexplained vaginal bleeding or endometrial hyperplasia with atypia or endometrial carcinoma, patients using systemic corticosteroids for life-saving purposes, coadministration with strong CYP3A4 inducers, simvastatin, lovastatin, or CYP3A substrates with narrow therapeutic ranges
<b>Required Medical Information</b>	Diagnosis of covered use, attestation surgery is not an option for the patient or has not been curative, submission of baseline serum potassium, AST, ALT, and alkaline phosphatase, pregnancy status for female patients of childbearing potential.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to endocrinology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## KOSELUGO (selumetinib)

---

### Products Affected

- KOSELUGO

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with moderate or strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use, submission of Child-Pugh score or liver function testing results, pregnancy status for female patients of childbearing potential.
Age Restrictions	Initiation: 2-17 years of age. Continuation: 2 years of age or older.
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. Selumetinib is indicated in pediatric patients and will not be approved for adults unless the patient started on the medication prior to 18 years of age.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## KRAZATI (adagrasib)

---

### Products Affected

- KRAZATI

PA Criteria	Criteria Details
Exclusion Criteria	Congenital long QT syndrome, coadministration with strong CYP3A4 inducers or drugs that prolong the QT interval
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of KRAS G12C mutation, submission of previous systemic treatment(s) tried.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# LAPATINIB

## Products Affected

- *lapatinib ditosylate*

PA Criteria	Criteria Details
Exclusion Criteria	Uncorrected hypokalemia, uncorrected hypomagnesemia
Required Medical Information	Diagnosis of covered use, submission of baseline potassium and magnesium levels, pregnancy status for female patients of childbearing potential, and depending on indication, confirmation that the treatment regimen will include concomitant use of either capecitabine or letrozole. For patients who will be using lapatinib with capecitabine, submission of prior therapies tried and failed.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# LEDIPASVIR/SOFOSBUVIR

## Products Affected

- HARVONI ORAL PACKET 45-200 MG
- HARVONI ORAL TABLET 90-400 MG
- *ledipasvir-sofosbuvir*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use, laboratory confirmation of hepatitis C virus (HCV) genotype 1a, 1b, 4, 5, or 6 infection, submission of baseline HCV RNA level, documentation of whether cirrhosis is present or not and whether or not it is compensated or decompensated, confirmation of whether patient is treatment-naïve or treatment-experienced, confirmation a test for HBV infection (HBsAg and anti-HBc) was completed.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Treatment-experienced pts w/genotype 1 and compensated cirrhosis, 24 weeks. All others, 12 weeks.
<b>Other Criteria</b>	PA applies to all. For treatment-naïve patients without cirrhosis who have pre-treatment HCV RNA less than 6 million IU/mL, 8 weeks of therapy may be considered by the provider. For approval of brand Harvoni 90 mg/400 mg, the patient must have tried and failed to have an adequate response to or had an intolerance to ledipasvir/sofosbuvir 90 mg/400 mg.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# LENALIDOMIDE

## Products Affected

- *lenalidomide*
- REVLIMID

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Pregnancy, chronic lymphocytic leukemia (outside of a controlled clinical trial)
<b>Required Medical Information</b>	Diagnosis of covered use, pregnancy status for female patients of childbearing potential. For maintenance therapy in patients with multiple myeloma following autologous hematopoietic stem cell transplant (auto-HSCT), submission of absolute neutrophil count (with the requirement it is at least 1,000/mcL) and platelet count (with the requirement it is at least 75,000/mcL). For mantle cell lymphoma, documentation of at least two prior therapies tried, one of which included bortezomib (or a documented contraindication to bortezomib). For follicular lymphoma and marginal zone lymphoma, submission of prior treatments tried and attestation medication will be coadministered with a rituximab product. For transfusion-dependent anemia due to myelodysplastic syndromes, documentation of a 5q cytogenetic abnormality.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to hematology and oncology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024



## LENVIMA (lenvatinib)

### Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	Uncorrected electrolyte abnormalities, uncontrolled hypertension
Required Medical Information	Diagnosis of covered use, submission of baseline blood pressure, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## LEUKINE (sargramostim, GM-CSF)

---

### Products Affected

- LEUKINE INJECTION SOLUTION  
RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	PA applies to all. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# LIDOCAINE TRANSDERMAL PATCHES

---

## Products Affected

- *lidocaine external patch 5 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. FDA-approved only for postherpetic neuralgia. Requests for other indications will not be approved.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## LIVMARLI (maralixibat)

### Products Affected

- LIVMARLI

PA Criteria	Criteria Details
Exclusion Criteria	History of liver transplant, clinical evidence of decompensated cirrhosis
Required Medical Information	Diagnosis of covered use confirmed by molecular genetic testing, attestation drug-induced pruritus has been ruled out, attestation patient has tried and failed at least two of the following medications for pruritus: ursodiol, cholestyramine, naltrexone, rifampin.
Age Restrictions	
Prescriber Restrictions	Restricted to gastroenterology and hepatology
Coverage Duration	1 year
Other Criteria	PA applies to all. Attestation of improvement in pruritus symptoms and confirmation the patient has not progressed to portal hypertension or has had a hepatic decompensation event since the previous authorization will be required for subsequent reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# LIVTENCITY (maribavir)

## Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use including a documented history of hematopoietic stem cell or solid organ transplant, submission of previous anti-CMV medication(s) patient has tried and failed (at least one of cidofovir, foscarnet, ganciclovir, valganciclovir).
Age Restrictions	12 years of age or older
Prescriber Restrictions	Restricted to hematology, infectious diseases, oncology, and transplant specialty
Coverage Duration	8 weeks
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# LODOCO (colchicine)

## Products Affected

- LODOCO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Renal failure, severe hepatic impairment, pre-existing blood dyscrasias, coadministration with strong CYP3A4 or P-glycoprotein inhibitors
<b>Required Medical Information</b>	Diagnosis, documented by either (1) prior acute coronary syndrome, (2) prior ischemic stroke, transient ischemic attack, or carotid artery stenosis greater than 50%, (3) prior coronary revascularization, (4) proven coronary artery disease on invasive coronary angiography or computer tomography angiography, (5) coronary-artery calcium score greater than or equal to 300 Agatston units, (6) aortic atherosclerotic disease, or (7) symptomatic peripheral vascular disease, submission of estimated glomerular filtration rate (eGFR) or creatinine clearance (or serum creatinine, actual body weight, and height to calculate estimated creatinine clearance) with a requirement the eGFR or creatinine clearance is greater than or equal to 15 mL/min, and attestations patient (1) does not have severe hepatic impairment, and (2) has had a recent complete blood count and does not have evidence of any cytopenia, and (3) does not have NYHA functional Class 3 or 4 heart failure.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to cardiology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. This product is not indicated for the treatment of gout and will not be authorized for this use.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

3/1/2024

PA Criteria	Criteria Details
Part B Prerequisite	No

3/1/2024

# LONSURF (trifluridine/tipiracil)

## Products Affected

- LONSURF

PA Criteria	Criteria Details
Exclusion Criteria	Moderate or severe hepatic impairment
Required Medical Information	Diagnosis of covered use, submission of prior therapies used for indication, submission of ALT, AST, and bilirubin, pregnancy status for female patients of childbearing potential. For metastatic colorectal cancer, documentation of KRAS status.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



# LORBRENA (lorlatinib)

---

## Products Affected

- LORBRENA ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A inducers, uncontrolled hypertension
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of ALK-positive tumor, baseline blood pressure, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# LUMAKRAS (sotorasib)

## Products Affected

- LUMAKRAS

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A inducers, coadministration with proton pump inhibitors or H2 receptor antagonists
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of KRAS G12C mutation, submission of previous systemic treatment(s) tried.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# LUPKYNIS (voclosporin)

## Products Affected

- LUPKYNIS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Severe hepatic impairment, coadministration with strong CYP3A4 inhibitors, moderate or strong CYP3A4 inducers, or cyclophosphamide, hypertensive emergency or a baseline blood pressure above 165/105 mmHg
<b>Required Medical Information</b>	Diagnosis of covered use including documentation of biopsy-proven Class III, IV, or V lupus nephritis, attestation patient will be taking concurrently with mycophenolate mofetil and corticosteroids, submission of estimated glomerular filtration rate (eGFR), urine protein to creatinine ratio (UPCR), baseline blood pressure, pregnancy status for female patients of childbearing potential, and any previous therapies tried.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initially 6 months, then 1 year
<b>Other Criteria</b>	PA applies to all. For approval, the patient must have tried and failed to have an adequate response to or had an intolerance/contraindication to Benlysta (belimumab) and have a UPCR of at least 1.5 mg/mg. Documentation of a positive response to therapy will be required for initial reauthorization after the first 6 months. Maintenance of a clinical benefit, attestation that prescriber believes benefits of continuing therapy outweigh the potential risks to the patient, and updated eGFR and blood pressure since the previous authorization will be required for subsequent annual reauthorizations.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

3/1/2024

PA Criteria	Criteria Details
Part B Prerequisite	No

3/1/2024

## LYBALVI (olanzapine/samidorphan)

### Products Affected

- LYBALVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Dementia-related psychosis, coadministration with opioids, levodopa, dopamine agonists, or strong CYP3A inducers, acute opioid withdrawal, end-stage renal disease
<b>Required Medical Information</b>	Diagnosis of covered use, confirmation patient has previously tried and failed, had an intolerance to, or had a contraindication to at least one generic second-generation antipsychotic with low incidence of metabolic side effects (e.g., aripiprazole, ziprasidone), attestation patient has had a trial of generic olanzapine with documentation showing a positive therapeutic benefit but unacceptable weight gain (greater than or equal to a 7% gain from baseline body weight) while using olanzapine.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to neurology and psychiatry
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only. Reduction in or stabilization of body weight since the previous authorization will be required for subsequent reauthorizations.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# LYNPARZA (olaparib)

## Products Affected

- LYNPARZA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with moderate or strong CYP3A inducers, baseline cytopenias
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of applicable mutations and previous therapies tried and failed depending on cancer type as necessary, submission of baseline CBC.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology and urology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## LYTGOBI (futibatinib)

### Products Affected

- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with dual strong CYP3A4/P-glycoprotein inhibitors or inducers
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of FGFR2 fusion or rearrangement, submission of previous systemic treatment(s) tried, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# MAVENCLAD (cladribine)

## Products Affected

- MAVENCLAD (10 TABS)
- MAVENCLAD (4 TABS)
- MAVENCLAD (5 TABS)
- MAVENCLAD (6 TABS)
- MAVENCLAD (7 TABS)
- MAVENCLAD (8 TABS)
- MAVENCLAD (9 TABS)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Current malignancy, pregnancy, HIV or other active chronic infection (e.g., hepatitis or tuberculosis), lymphocyte count below normal limit before first course or less than 800 cells/microliter before second course, creatinine clearance below 60 mL/min, Child-Pugh score greater than 6, patients with clinically isolated syndrome (CIS)
<b>Required Medical Information</b>	Diagnosis of covered use, pregnancy status for female patients of childbearing potential, submission of previous therapies tried and failed, lymphocyte count, submission of creatinine clearance (or serum creatinine, actual body weight, and height to calculate estimated creatinine clearance).
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to neurology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. For approval, the patient must have tried and failed to have an adequate response to or had an intolerance to at least two on-formulary medications for the maintenance treatment of relapsing forms of multiple sclerosis. Documentation of a positive response to therapy, confirmation the patient has no active infection, and updated lymphocyte count and creatinine clearance since the previous authorization will be required for reauthorization. After the completion of 2 treatment courses (2 years' treatment), additional treatment courses are not recommended over the following 2 years because of malignancy risk. Re-initiating treatment after those 2 years have passed has not been studied. Requests for therapy for a combined total of greater than 2 years will not be approved.

3/1/2024



PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# MAVYRET (glecaprevir/pibrentasvir)

## Products Affected

- MAVYRET

PA Criteria	Criteria Details
Exclusion Criteria	Moderate or severe hepatic impairment (Child-Pugh class B or C), coadministration with rifampin or atazanavir
Required Medical Information	Diagnosis of covered use, laboratory confirmation of hepatitis C virus (HCV), documentation of whether cirrhosis is present or not and whether or not it is compensated or decompensated, confirmation a test for HBV infection (HBsAg and anti-HBc) was completed.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Criteria for coverage duration will be applied consistent with current AASLD-IDSA guidance.
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# MECASERMIN

## Products Affected

- INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	Patients with closed epiphyses
Required Medical Information	Diagnosis of covered use, documentation of primary insulin-like growth factor (IGF-1) deficiency or growth hormone gene deletion in patients who have developed neutralizing antibodies to growth hormone, submission of IGF-1 level and growth hormone level.
Age Restrictions	
Prescriber Restrictions	Restricted to endocrinology and nephrology
Coverage Duration	6 months
Other Criteria	PA applies to all. Updated IGF-1 and growth hormone levels since the previous authorization will be required for subsequent reauthorizations. Mecasermin is not indicated as a growth hormone replacement and will not be approved for this indication.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## MEDICATIONS WITH HEART FAILURE RISK

### Products Affected

- *cilostazol*
- *itraconazole oral*
- *minoxidil oral*
- MULTAQ
- *pioglitazone hcl*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use, attestation prescriber is aware of the medication's risk when used in patients with heart failure and benefit to the patient outweighs the risk of worsening condition.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. Members in the chronic condition special needs plan (C-SNP) have a diagnosis of heart failure. The medications covered by this policy have known risks in patients with heart failure and should only be used if the benefits of the medication clearly outweigh the risk to the patient.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# MEGESTROL IN OLDER PATIENTS

## Products Affected

- *megestrol acetate oral suspension 40 mg/ml, 625 mg/5ml*

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of covered use.
Age Restrictions	PA applies to patients 65 years of age or older. PA does not apply to patients 64 years of age or younger.
Prescriber Restrictions	PA not required for hematology or oncology
Coverage Duration	1 year
Other Criteria	PA applies to all except hematology and oncology.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# MEKINIST (trametinib)

## Products Affected

- MEKINIST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of BRAF V600E or V600K mutation, pregnancy status for female patients of childbearing potential. For all indications except BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma, attestation that therapy will be used in combination with dabrafenib.
Age Restrictions	
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## METHOTREXATE INJECTABLE (SUBCUTANEOUS)

### Products Affected

- OTREXUP SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.4ML, 12.5 MG/0.4ML, 15 MG/0.4ML, 17.5 MG/0.4ML, 20 MG/0.4ML, 22.5 MG/0.4ML, 25 MG/0.4ML
- RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of covered use, documentation of intolerance or inadequate response to oral or non-subcutaneous injectable forms of methotrexate.
Age Restrictions	
Prescriber Restrictions	Restricted to rheumatology and dermatology
Coverage Duration	1 year
Other Criteria	PA applies to all. These medications are not approved for use in oncology and will not be approved for cancer diagnoses.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# MIGLUSTAT

## Products Affected

- *miglustat*

PA Criteria	Criteria Details
Exclusion Criteria	Severe renal impairment (CrCl less than 30 mL/min)
Required Medical Information	Diagnosis of covered use, documentation that enzyme replacement is not a therapeutic option (e.g., allergy, poor central venous access, hypersensitivity).
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



# MYALEPT (metreleptin)

## Products Affected

- MYALEPT

PA Criteria	Criteria Details
Exclusion Criteria	General obesity not associated with congenital leptin deficiency
Required Medical Information	Diagnosis of covered use, submission of leptin level laboratory test result confirming leptin deficiency, baseline HbA1c, fasting glucose, fasting triglyceride levels, and weight.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. Updated patient weight, HbA1c, fasting glucose, and fasting triglyceride levels since the previous authorization will be required for subsequent annual reauthorizations. Metreleptin is not established as a treatment for nonalcoholic steatohepatitis, complications of partial lipodystrophy, HIV-related lipodystrophy, or metabolic disease without generalized lipodystrophy, and submissions for these uses will not be approved.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## MYCAPSSA (octreotide)

---

### Products Affected

- MYCAPSSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of prior use of either injectable octreotide or lanreotide and attestation to its successful treatment of acromegaly using clinical biomarkers or chart notes.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to endocrinology
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## MYTESI (crofelemer)

---

### Products Affected

- MYTESI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, attestation infectious causes of diarrhea have been ruled out.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## NAMZARIC (memantine and donepezil)

---

### Products Affected

- NAMZARIC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of documentation that the patient has been stabilized on donepezil 10 mg daily.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## NATPARA (parathyroid hormone)

---

### Products Affected

- NATPARA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, documentation that (albumin-corrected) serum calcium is greater than 7.5 mg/dL and confirmation that 25-hydroxyvitamin D stores are sufficient.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to endocrinology
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## NERLYNX (neratinib)

### Products Affected

- NERLYNX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coadministration with proton pump inhibitors, strong CYP3A4 inhibitors, moderate CYP3A4 and P-glycoprotein dual inhibitors, or moderate or strong CYP3A4 inducers
<b>Required Medical Information</b>	Diagnosis of covered use, submission of genetic tumor testing confirming the primary tumor type is HER2-positive, confirmation member has completed adjuvant trastuzumab-based therapy or will be using in combination with capecitabine, pregnancy status for female patients of childbearing potential. For advanced or metastatic breast cancer, submission of previous anti-HER2 regimens used.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to oncology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## NEXAVAR (sorafenib)

---

### Products Affected

- *sorafenib tosylate*

PA Criteria	Criteria Details
Exclusion Criteria	Congenital long QT syndrome, coadministration with strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use, submission of pregnancy status for female patients of childbearing potential. For differentiated thyroid carcinoma, attestation patient has disease refractory to radioactive iodine therapy.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## NINLARO (ixazomib)

### Products Affected

- NINLARO

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use, documentation that medication will be administered concomitantly with lenalidomide and dexamethasone, documentation of prior therapy regimen for multiple myeloma, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



# NITISINONE

## Products Affected

- *nitisinone*
- ORFADIN ORAL SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of succinylacetone in urine or plasma.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initially 6 months, then 1 year
Other Criteria	PA applies to all. Updated liver function tests, urine succinylacetone levels, alpha-fetoprotein level, serum tyrosine level, and serum phenylalanine level since the previous authorization will be required for subsequent reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# NUCALA (mepolizumab)

## Products Affected

- NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML
- NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use. For eosinophilic asthma, documentation that patient's symptoms are poorly controlled with inhaled corticosteroids, submission of pulmonary function test results including FEV1, frequency of inhaled short-acting beta2-agonist therapy, frequency of daily and nighttime symptoms and exacerbations, and effect of exacerbations on activity, submission of blood eosinophil count of at least 150 cells/mcL obtained within 6 weeks of therapy initiation or at least 300 cells/mcL within 12 months of therapy initiation. For chronic rhinosinusitis with nasal polyps, documentation of treatment with an intranasal corticosteroid for at least 8 weeks, a contraindication to the use of intranasal corticosteroids, or therapy is not otherwise advisable.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Restricted to allergy, hematology, immunology, otorhinolaryngology, pulmonology, and rheumatology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. Continuation of therapy requests require objective documentation from the prescriber that the patient's symptoms have improved. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
<b>Indications</b>	All Medically-accepted Indications.

3/1/2024

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## NUEDEXTA (dextromethorphan and quinidine)

### Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	Prolonged QT interval, congenital long QT syndrome, heart failure, history suggestive of torsades de pointes, AV block without implanted pacemaker, administration of non-selective monoamine oxidase inhibitors within 14 days of initiation
Required Medical Information	Diagnosis of covered use, submission of ECG (specifically QT interval).
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to neurology and psychiatry
Coverage Duration	1 year
Other Criteria	PA applies to all. The medication will not be approved for agitation or Alzheimer's disease without pseudobulbar affect as this is considered an off-label use.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## NUPLAZID (pimavanserin)

### Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Dementia-related psychosis unrelated to Parkinson's disease psychosis, cardiac arrhythmias, symptomatic bradycardia, congenital QT prolongation, coadministration with moderate or strong CYP3A4 inducers or drugs that prolong the QT interval, hypokalemia, hypomagnesemia
<b>Required Medical Information</b>	Diagnosis of covered use.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# OCALIVA (obeticholic acid)

## Products Affected

- OCALIVA ORAL TABLET 10 MG, 5 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Complete biliary obstruction, decompensated cirrhosis (Child-Pugh B or C) or prior decompensation event, compensated cirrhosis with evidence of portal hypertension (e.g., ascites, gastroesophageal varices, persistent thrombocytopenia)
<b>Required Medical Information</b>	Diagnosis of covered use, documentation either (1) drug will be used in combination with ursodeoxycholic acid (UDCA) and UDCA has been used for at a stable dosage for at least 3 months or (2) patient had intolerance to UDCA, submission of baseline LFTs including ALP and total bilirubin, attestation patient does not have evidence of portal hypertension and has not had a prior decompensation event.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initially 6 months, then 1 year
<b>Other Criteria</b>	PA applies to all. Documentation of a reduction in ALP will be required after the first 6 months. Maintenance of a clinical benefit will be required for subsequent annual reauthorizations.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## ODOMZO (sonidegib)

---

### Products Affected

- ODOMZO

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy, coadministration with strong CYP3A4 inhibitors or moderate or strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use, attestation patient is not a candidate for surgery or radiation therapy or carcinoma has recurred following surgery or radiation therapy, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## OFEV (nintedanib)

### Products Affected

- OFEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Moderate or severe (Child-Pugh class B or C) hepatic impairment, coadministration of a dual P-glycoprotein/CYP3A4 inducer
<b>Required Medical Information</b>	Diagnosis of covered use, submission of liver function tests or Child-Pugh status, pregnancy status for female patients of childbearing potential. For chronic fibrosing interstitial lung diseases with a progressive phenotype and systemic sclerosis-associated interstitial lung disease diagnoses, submission of HRCT scan showing fibrosis of the lungs within the previous 12 months.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to pulmonology or rheumatology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. Updated liver function testing or Child-Pugh score since the previous authorization will be required for subsequent reauthorizations.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024



## OGSIVEO (nirogacestat)

### Products Affected

- OGSIVEO

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with moderate or strong CYP3A inhibitors or inducers
Required Medical Information	Diagnosis of covered use with documentation of tumor progression, submission of pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology and sarcoma specialty
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## OJJAARA (mometotinib)

---

### Products Affected

- OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	Active infection, uncontrolled acute or chronic liver disease
Required Medical Information	Diagnosis of covered use.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ONUREG (azacitidine)

### Products Affected

- ONUREG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, documentation patient achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy and cannot complete intensive curative therapy, submission of absolute neutrophil count, submission of pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. This dosage form is not intended to be a substitute for or substituted for injectable azacitidine.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## OPFOLDA (miglustat)

### Products Affected

- OPFOLDA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of previous enzyme replacement therapies tried and failed, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ORENITRAM (treprostinil)

---

### Products Affected

- ORENITRAM
- ORENITRAM MONTH 1
- ORENITRAM MONTH 2
- ORENITRAM MONTH 3

PA Criteria	Criteria Details
Exclusion Criteria	Moderate or severe (Child-Pugh class B or C) hepatic impairment
Required Medical Information	Diagnosis of covered use.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to cardiology and pulmonology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# OREXIN RECEPTOR ANTAGONISTS

## Products Affected

- DAYVIGO ORAL TABLET 10 MG, 5 MG
- QUVIVIQ

PA Criteria	Criteria Details
Exclusion Criteria	Narcolepsy
Required Medical Information	Diagnosis of covered use. Patient must have tried and failed to tolerate or had an inadequate response to two covered alternative therapies recommended by the American Academy of Sleep Medicine (doxepin, eszopiclone, ramelteon, suvorexant, temazepam, zaleplon, zolpidem) including one non-suvorexant therapy for sleep maintenance (doxepin, eszopiclone, temazepam) if that is the diagnosis of covered use.
Age Restrictions	PA applies to patients 65 years of age or older. PA does not apply to patients 64 years of age or younger.
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ORILISSA (elagolix)

### Products Affected

- ORILISSA ORAL TABLET 150 MG, 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy, severe hepatic impairment (Child-Pugh class C), known osteoporosis, coadministration with OATP1B1 inhibitors
Required Medical Information	Diagnosis of covered use, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to endocrinology and gynecology
Coverage Duration	Up to 24 months based on liver function and coexisting dyspareunia. See "Other Criteria" section.
Other Criteria	PA applies to all. For endometriosis with dyspareunia or in women with moderate hepatic impairment, 6 months. For endometriosis without dyspareunia, 150 mg daily for 24 months. Use of this drug for more than 2 years increases risk of bone loss and requests for therapy for more than 2 years will not be approved.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ORKAMBI (lumacaftor/ivacaftor)

---

### Products Affected

- ORKAMBI

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of cystic fibrosis mutation test confirming presence of two copies of the F508del mutation in the CFTR gene.
Age Restrictions	
Prescriber Restrictions	Restricted to pulmonology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



## ORSERDU (elacestrant)

---

### Products Affected

- ORSERDU

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment (Child-Pugh class C), coadministration with moderate or strong CYP3A inhibitors or inducers
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of ESR1 mutation and liver function testing or Child-Pugh score, documentation of prior endocrine therapy/therapies patient has tried and failed. For female patients, attestation patient is postmenopausal.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## OXBRYTA (voxelotor)

### Products Affected

- OXBRYTA

PA Criteria	Criteria Details
Exclusion Criteria	Hemoglobin greater than 10.5 g/dL
Required Medical Information	Diagnosis of covered use, submission of hemoglobin level, documentation of treatment failure with at least a three-month trial of hydroxyurea or a hematologic toxicity requiring discontinuation of a prior regimen of hydroxyurea therapy.
Age Restrictions	
Prescriber Restrictions	Restricted to hematology
Coverage Duration	Initially 6 months, then 1 year
Other Criteria	PA applies to all. Submission of improved hemoglobin level from baseline will be required for initial reauthorization after the first 6 months. Documentation of continued hemoglobin level improvement or maintenance of initial hemoglobin level improvement will be required for subsequent reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## OXERVATE (cenegermin-bkbj)

---

### Products Affected

- OXERVATE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use.
Age Restrictions	
Prescriber Restrictions	Restricted to optometry and ophthalmology
Coverage Duration	8 weeks
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# OXYBATE SALT MEDICATIONS

## Products Affected

- XYREM
- XYWAV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coadministration with sedative hypnotics
<b>Required Medical Information</b>	Diagnosis of covered use confirmed with documentation from a sleep study, submission of previous therapies used for diagnosis (see Other Criteria).
<b>Age Restrictions</b>	7 years of age or older
<b>Prescriber Restrictions</b>	Restricted to neurology, psychiatry, and sleep medicine
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. For adults with excessive daytime sleepiness associated with narcolepsy, drugs in this policy will be authorized only if the patient previously tried and had an inadequate clinical response, intolerance, or contraindication to (1) armodafinil or modafinil and (2) solriamfetol. Medications covered in this policy are not indicated to treat insomnia and will not be approved for this use.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## PALYNZIQ (pegvaliase-pqpz)

### Products Affected

- PALYNZIQ

PA Criteria	Criteria Details
Exclusion Criteria	Blood phenylalanine concentration below 600 micromol/L
Required Medical Information	Diagnosis of covered use, submission of blood phenylalanine concentration, documentation patient has tried and failed to respond to at least 30 days of sapropterin therapy.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. For initial approval, documentation of a phenylalanine concentration above 600 micromol/L while using sapropterin therapy is required. Reduction in blood phenylalanine concentration from pre-treatment baseline will be required for initial reauthorization after the first year. Documentation of continued phenylalanine level improvement or maintenance of initial phenylalanine level improvement will be required for subsequent reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## PANRETIN (alitretinoin)

---

### Products Affected

- PANRETIN

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy, requirement for systemic Kaposi's sarcoma therapy (more than 10 new Kaposi's sarcoma lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary Kaposi's sarcoma, or symptomatic visceral involvement)
Required Medical Information	Diagnosis of covered use.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to dermatology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# PARKINSON'S DISEASE "OFF" EPISODE (AS NEEDED) THERAPIES

## Products Affected

- *apomorphine hcl subcutaneous*
- INBRIJA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	For Inbrija, administration of non-selective monoamine oxidase inhibitors within 14 days of initiation, asthma, COPD, or other chronic underlying lung disease.
<b>Required Medical Information</b>	Diagnosis of covered use, attestation patient is experiencing "off" episodes despite carbidopa/levodopa therapy, prescription claims or documentation from physician showing patient (a) has tried and failed or had an intolerance to medications from at least two different drug classes that can help to reduce "off" episodes (COMT inhibitors, dopamine agonists, monoamine oxidase B inhibitors), or (b) has tried and failed or had an intolerance to one medication from a drug class that can help to reduce "off" episodes if they have contraindications to two of these drug classes, or (c) has contraindications to all three drug classes that can help to reduce "off" episodes.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to neurology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# PCSK9 INHIBITORS

## Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use, submission of current or previous lipid-lowering therapies (see Other Criteria).
<b>Age Restrictions</b>	For Repatha, 10 years of age or older. For Praluent, 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only. For approval, the patient must currently be using a statin plus ezetimibe or the patient must have tried and failed to have an adequate response to or had an intolerance to at least two statins or one statin and ezetimibe. At least one statin previously tried and failed must be a hydrophilic statin.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024



## PDE5 INHIBITORS (PAH)

### Products Affected

- *alyq*
- *sildenafil citrate oral suspension reconstituted*
- *sildenafil citrate oral tablet 20 mg*
- *tadalafil (pah)*

PA Criteria	Criteria Details
Exclusion Criteria	For tadalafil, diagnosis of severe (Child-Pugh class C) hepatic impairment, creatinine clearance below 30 mL/min or on hemodialysis
Required Medical Information	Diagnosis of covered use.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to cardiology and pulmonology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# PEGFILGRASTIM

## Products Affected

- NEULASTA ONPRO
- NEULASTA SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE
- UDENYCA
- UDENYCA ONBODY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of FDA-approved indication.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	PA applies to all. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## PEMAZYRE (pemigatinib)

### Products Affected

- PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with moderate or strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of either FGFR1 rearrangement or FGFR2 fusion or rearrangement, submission of previous systemic treatment(s) tried, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## PIQRAY (alpelisib)

### Products Affected

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use, submission of genetic tumor testing confirming the primary tumor type is HR-positive, HER2-negative, and PIK3CA-mutated, attestation that patient has advanced or metastatic disease and will be taking concurrently with fulvestrant, submission of at least one endocrine-based (e.g., anastrozole, exemestane, letrozole, tamoxifen, etc.) regimen tried and failed, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# PIRFENIDONE

---

## Products Affected

- *pirfenidone oral tablet 267 mg, 801 mg*

PA Criteria	Criteria Details
Exclusion Criteria	End-stage renal disease on dialysis, severe (Child-Pugh class C) hepatic impairment
Required Medical Information	Diagnosis of covered use, submission of liver function tests or Child-Pugh status.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to pulmonology
Coverage Duration	1 year
Other Criteria	PA applies to all. Updated liver function testing or Child-Pugh score since the previous authorization will be required for subsequent reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## POMALYST (pomalidomide)

---

### Products Affected

- POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of covered use, submission of pregnancy status for female patients of childbearing potential. For multiple myeloma, documentation has used a lenalidomide-based treatment regimen. For Kaposi sarcoma, attestation patient is HIV-negative or patient is using highly-active antiretroviral therapy.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# PRETOMANID

## Products Affected

- PRETOMANID

PA Criteria	Criteria Details
Exclusion Criteria	Inability to use bedaquiline or linezolid, drug-sensitive tuberculosis, coadministration with moderate or strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use, attestation pretomanid will be used in combination with bedaquiline and linezolid.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to infectious diseases and pulmonology
Coverage Duration	26 weeks
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## PREVYMIS (letermovir)

### Products Affected

- PREVYMIS ORAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Severe hepatic impairment (Child-Pugh class C), coadministration with ergot alkaloids, pimozide, or pitavastatin or simvastatin when coadministered with cyclosporine
<b>Required Medical Information</b>	Diagnosis of covered use, submission of day number post-transplant, documentation of any previous doses of letermovir. For use after kidney transplant, documentation patient is high risk, defined as donor CMV seropositive/recipient CMV seronegative (D+/R-), submission of explanation why valganciclovir is contraindicated or cannot be used for prophylaxis.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to hematology, oncology, transplant specialist, and infectious diseases
<b>Coverage Duration</b>	Through 100 days post-transplant for HSCT or through 200 days post-transplant for kidney transplant
<b>Other Criteria</b>	PA applies to all.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024



# PRIOR AUTHORIZATION TO OVERRIDE SPECIALTY RESTRICTIONS

## Products Affected

- CORLANOR
- *diclofenac sodium external gel 3 %*
- PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML
- PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- *tazarotene external cream*
- *tazarotene external gel*
- TAZORAC EXTERNAL CREAM 0.05 %
- VABOMERE
- VEMLIDY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use. Drugs in this policy require prior authorization but are exempted from this requirement if prescribed by certain specialists (see Prescriber Restriction).
Age Restrictions	
Prescriber Restrictions	(a) for Corlanor: cardiology exempt, (b) for diclofenac 3% gel: dermatology or oncology exempt, (c) for Pegasys: gastroenterology, hepatology, or infectious diseases exempt, (d) for Symlin: endocrinology exempt, (e) for tazarotene and Tazorac: dermatology exempt, (f) for Vabomere: infectious diseases or nephrology exempt, (g) for Vemlidy: gastroenterology, hepatology, or infectious diseases exempt
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## PROCYSBI (cysteamine)

### Products Affected

- PROCYSBI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, documentation that patient has tried and failed or had an intolerance to immediate-release cysteamine.
Age Restrictions	1 year of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. For approval, the patient must have tried and failed to have an adequate response to, had an intolerance to, or have a contraindication to therapy with immediate-release cysteamine.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# PROLIA (denosumab)

## Products Affected

- PROLIA SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	Hypocalcemia, pregnancy
Required Medical Information	Diagnosis of covered use, submission of calcium level, pregnancy status for female patients of childbearing potential. "High risk for fracture" is defined as (1) a history of osteoporotic fracture or (2) multiple risk factors for fracture or (3) patients who have failed or are intolerant of other available osteoporosis therapies, confirmation of osteoporosis diagnosis either through densitometry (T-score less than or equal to -2.5 at the total hip, femoral neck, or lumbar spine) or clinically (documented presence of fragility fracture).
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. Updated serum calcium level since the previous authorization will be required for subsequent reauthorizations. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
Indications	All Medically-accepted Indications.
Off Label Uses	

3/1/2024

PA Criteria	Criteria Details
Part B Prerequisite	No

3/1/2024

# PROMACTA (eltrombopag)

## Products Affected

- PROMACTA ORAL PACKET
- PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of platelet count. For immune thrombocytopenia (ITP), submission of previous therapies tried and failed (see Other Criteria). For thrombocytopenia in patients with chronic hepatitis C, attestation patient will be receiving interferon therapy to treat HCV. For aplastic anemia (AA), submission of immunosuppressive therapy that will be used concomitantly or, in the case of refractory disease, submission of therapy or therapies tried and failed.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	For ITP, initially 12 weeks, then 1 year. For AA, 6 months. For all other indications, 1 year.
Other Criteria	PA applies to all. Initial approval for ITP requires (1) platelet count less than $30 \times 10^9/L$ or less than $50 \times 10^9/L$ with documented increased risk of bleeding and (2) documentation patient has undergone splenectomy and/or tried and failed two different ITP therapies including systemic corticosteroids, immunoglobulins, danazol, fostamatinib, or cytotoxics/immunosuppressants such as rituximab. For ITP, documentation of an improvement in platelet count will be required for initial reauthorization after the first 12 weeks. Maintenance of a clinical benefit will be required for subsequent annual reauthorizations. Initial approval in patients with chronic hepatitis C requires platelet count less than $75 \times 10^9/L$ . Initial approval for aplastic anemia requires platelet count less than $30 \times 10^9/L$ . Updated platelet count since the previous authorization will be required for subsequent reauthorizations. Not indicated for treatment of patients with myelodysplastic syndrome and will not be approved for this use.

3/1/2024

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## PROMETHAZINE IN OLDER PATIENTS

### Products Affected

- *promethazine hcl oral syrup*
- *promethazine hcl oral tablet*
- *promethazine hcl rectal suppository 12.5 mg, 25 mg*
- PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use. For allergic conditions, documentation must be submitted showing patient has tried and failed or had an inadequate response to a second-generation antihistamine.
<b>Age Restrictions</b>	PA applies to patients 65 years of age or older. PA does not apply to patients 64 years of age or younger.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. Promethazine is a potent anticholinergic considered high-risk in older patients due to risks of confusion, dry mouth, constipation, and decreased clearance with advanced age.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# PROSTATE CANCER ORAL MEDICATIONS

## Products Affected

- *abiraterone acetate oral tablet 250 mg*
- ERLEADA
- NUBEQA
- XTANDI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	For abiraterone, severe hepatic impairment (Child-Pugh class C), uncontrolled hypertension
<b>Required Medical Information</b>	Diagnosis of covered use. For Nubeqa, documentation of other treatments tried (see Other Criteria). For abiraterone, confirmation patient will receive concurrent prednisone, submission of baseline ALT, AST, bilirubin, and serum potassium level.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to oncology and urology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only. Nubeqa will be authorized only if the patient previously tried and had an inadequate clinical response or an intolerance to both Erleada and Xtandi.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024



## PYRUKYND (mitapivat)

### Products Affected

- PYRUKYND
- PYRUKYND TAPER PACK ORAL TABLET  
THERAPY PACK 5 MG, 7 X 20 MG & 7 X 5  
MG, 7 X 50 MG & 7 X 20 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coadministration with hematopoietic stimulating agents or strong CYP3A4 inhibitors or inducers
<b>Required Medical Information</b>	Diagnosis of covered use, submission of test confirming presence of at least two mutant alleles in the PKLR gene, of which at least one is a missense mutation, and where the mutations are not a homozygous R479H mutation, hemoglobin level within the previous 3 months less than or equal to 10 mg/dL, number of red blood cell (RBC) transfusions in the previous 12 months (to establish baseline severity only).
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to hematology or specialists in inborn errors of metabolism
<b>Coverage Duration</b>	Initially 6 months, then 1 year
<b>Other Criteria</b>	PA applies to all. For initial reauthorization, improvement of hemoglobin level and/or reductions in annualized rate of RBC transfusions is required. Continued improvement/stability in either hemoglobin level or reductions in RBC transfusional burden from baseline will be required for subsequent reauthorizations.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## QINLOCK (ripretinib)

### Products Affected

- QINLOCK

PA Criteria	Criteria Details
Exclusion Criteria	Uncontrolled hypertension, coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of previous kinase inhibitor therapies, baseline blood pressure reading, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## RADICAVA ORS (edaravone)

---

### Products Affected

- RADICAVA ORS
- RADICAVA ORS STARTER KIT

PA Criteria	Criteria Details
Exclusion Criteria	ALS duration of greater than 2 years
Required Medical Information	Diagnosis of covered use, submission of ALS Functional Rating Scale-Revised (ALSFRS-R) scoring (patient is required to have scores of 2 points or better on each of the 12 individual ALSFRS-R items).
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to neurology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## RAVICTI (glycerol phenylbutyrate)

### Products Affected

- RAVICTI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of baseline fasting plasma ammonia level, documentation patient has tried and failed, has a contraindication to, or could not tolerate sodium phenylbutyrate.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# RECORLEV (levoketoconazole)

## Products Affected

- RECORLEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Cirrhosis, acute, poorly-controlled chronic, or extensive metastatic liver disease, baseline AST or ALT greater than 3 times the upper limit of normal, recurrent symptomatic cholelithiasis, a prior history of drug-induced liver injury due to ketoconazole or any azole antifungal therapy that required discontinuation of treatment, prolonged QTcF interval greater than 470 msec at baseline, history of torsades de pointes, ventricular tachycardia, ventricular fibrillation, or prolonged QT syndrome, coadministration with drugs that cause QT prolongation associated with ventricular arrhythmias
<b>Required Medical Information</b>	Diagnosis of covered use, submission of 24-hour urine free cortisol (UFC) level demonstrating a baseline value more than 1.5 times the upper limit of normal (50 micrograms or 145 nmol), attestation pituitary gland surgery is not an option for the patient or has not been curative, electrocardiogram (including QTcF), and liver function tests all performed within 3 months of prior authorization request, documentation patient tried and failed at least one other therapy for Cushing's syndrome (e.g., mifepristone, osilodrostat, pasireotide).
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to endocrinology
<b>Coverage Duration</b>	Initially 6 months, then 1 year
<b>Other Criteria</b>	PA applies to all. Continuation requires documentation of clinically relevant response to therapy, including, but not limited to 24-hour UFC level. Recorlev is not approved for the treatment of fungal infections and will not be approved for this use.
<b>Indications</b>	All Medically-accepted Indications.

3/1/2024

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## RELYVRIO (sodium phenylbutyrate/taurursodiol)

---

### Products Affected

- RELYVRIO

PA Criteria	Criteria Details
Exclusion Criteria	Moderate or severe hepatic impairment, moderate or severe renal impairment, tracheostomy, permanent assisted ventilation
Required Medical Information	Diagnosis of covered use, submission of ALS Functional Rating Scale-Revised (ALSFRS-R) scoring (patient is required to have ALSFRS-R score greater than 20), submission of chart data showing patient is starting drug within 18 months of symptom onset, documentation patient is currently using, has tried and failed, has a contraindication to, or could not tolerate riluzole.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to neurology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## RETEVMO (selpercatinib)

### Products Affected

- RETEVMO ORAL CAPSULE 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	Uncontrolled hypertension, coadministration with moderate or strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of RET gene fusion or mutation, baseline blood pressure reading, pregnancy status for female patients of childbearing potential. For patients with RET fusion-positive thyroid cancer, documentation of previous radioactive iodine treatment or reason why radioactive iodine therapy is not appropriate.
Age Restrictions	12 years of age or older based on indication
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



## REZLIDHIA (olutasidenib)

---

### Products Affected

- REZLIDHIA

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with moderate or strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of IDH1 mutation, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# REZUROCK (belumosudil)

## Products Affected

- REZUROCK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of at least 2 previous therapies tried and failed for chronic graft-versus-host disease, pregnancy status for female patients of childbearing potential.
Age Restrictions	12 years of age or older
Prescriber Restrictions	Restricted to hematology, oncology, and transplant specialty
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# RIVFLOZA (nedosiran)

## Products Affected

- RIVFLOZA

PA Criteria	Criteria Details
Exclusion Criteria	Estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m <sup>2</sup>
Required Medical Information	Diagnosis of covered use, documentation of AGXT mutation confirmed by liver enzyme analysis or genetic testing, submission of 24-hour urinary oxalate (Uox) excretion with a requirement it is greater than or equal to 0.7 mmol (normalized to body surface area if patient is under 18 years of age) and estimated glomerular filtration rate (eGFR), attestation patient has not received a prior kidney or liver transplant, attestation patient will not be using in combination with lumasiran (Oxlumo).
Age Restrictions	9 years of age or older
Prescriber Restrictions	Restricted to nephrology and urology
Coverage Duration	Initially 6 months, then 1 year
Other Criteria	PA applies to all. Reauthorization requires documentation of clinically relevant response to therapy as evidenced by reduced Uox or plasma oxalate levels.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ROZLYTREK (entrectinib)

### Products Affected

- ROZLYTREK

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with moderate or strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, pregnancy status for female patients of childbearing potential. For non-small cell lung cancer, submission of test confirming presence of ROS1-positive tumor. For solid tumors, submission of evidence of a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation and attestation tumor is metastatic or surgical resection/other systemic therapies are unsatisfactory treatment options.
Age Restrictions	
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# RUBRACA (rucaparib)

## Products Affected

- RUBRACA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of deleterious BRCA mutation. For maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, documentation of response to platinum-based chemotherapy. For BRCA mutation-associated mCRPC, confirmation patient (1) has been treated with or is not a candidate for taxane-based chemotherapy and (2) is using a gonadotropin-releasing hormone analog or has had a bilateral orchiectomy.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology and urology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## RYDAPT (midostaurin)

### Products Affected

- RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, pregnancy status for female patients of childbearing potential. For acute myeloid leukemia, submission of test confirming presence of FLT3 mutation, documentation of other chemotherapy that will be coadministered with midostaurin.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# SAPROPTERIN

## Products Affected

- *sapropterin dihydrochloride oral packet*
- *sapropterin dihydrochloride oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of blood phenylalanine concentration.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initially 6 months, then 1 year
Other Criteria	PA applies to all. Reduction in blood phenylalanine concentration from pre-treatment baseline will be required for initial reauthorization. Documentation of continued phenylalanine level improvement or maintenance of initial phenylalanine level improvement will be required for subsequent reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## SCEMBLIX (asciminib)

### Products Affected

- SCEMBLIX ORAL TABLET 20 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of pregnancy status for female patients of childbearing potential. For use in patients with a T315I mutation, documentation patient has first tried and failed or become intolerant to ponatinib. For use in patients without a T315I mutation, documentation of other tyrosine kinase inhibitors tried and failed.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. For approval in T315I-mutation-positive CML, the patient must have tried and failed to have an adequate response to or had an intolerance to ponatinib.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



## SEDATIVE HYPNOTICS IN OLDER PATIENTS

### Products Affected

- *eszopiclone*
- *zaleplon*
- *zolpidem tartrate oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, documentation at least two of the following medications were tried and deemed ineffective or intolerable: Belsomra, doxepin tablets, ramelteon, and trazodone.
Age Restrictions	PA applies to patients 65 years of age or older. PA does not apply to patients 64 years of age or younger.
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. Sedative hypnotic medications are high-risk medications in older patients due to increased risks of cognitive impairment, delirium, unsteady gait, syncope, falls, fractures, and motor vehicle accidents.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## SEROSTIM (somatropin)

---

### Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION  
RECONSTITUTED 4 MG, 5 MG, 6 MG

PA Criteria	Criteria Details
Exclusion Criteria	Active malignancy, acute critical illness, active proliferative or severe non-proliferative diabetic retinopathy
Required Medical Information	Diagnosis of covered use.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. Serostim is indicated only for the treatment of HIV-associated cachexia/wasting and uses outside of this indication will not be approved.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## SIGNIFOR (pasireotide)

---

### Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment (Child-Pugh class C), uncorrected hypokalemia or hypomagnesemia
Required Medical Information	Diagnosis of covered use, submission of 24-hour urine free cortisol (UFC) level demonstrating a baseline value more than 1.5 times the upper limit of normal (50 micrograms or 145 nmol), attestation pituitary gland surgery is not an option for the patient or has not been curative, submission of ALT, aspartate aminotransferase, alkaline phosphatase, total bilirubin, and serum potassium and magnesium levels.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to endocrinology
Coverage Duration	Initially 6 months, then 1 year
Other Criteria	PA applies to all. Continuation requires documentation of clinically relevant response to therapy including, but not limited to 24-hour UFC level.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## SIMVASTATIN 80 mg per day

---

### Products Affected

- *ezetimibe-simvastatin oral tablet 10-80 mg*
- *simvastatin oral tablet 80 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, documentation that patient has been taking simvastatin 80 mg daily for 12 months or longer without adverse effects.
Age Restrictions	10 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. Not recommended as initial therapy nor for patients already taking lower doses of simvastatin whose response is inadequate.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## SIRTURO (bedaquiline)

### Products Affected

- SIRTURO

PA Criteria	Criteria Details
Exclusion Criteria	Drug-sensitive tuberculosis, latent infection, extra-pulmonary tuberculosis
Required Medical Information	Diagnosis of covered use, confirmation that Sirturo will be co-administered with pretomanid and linezolid or at least 3 other drugs proven to be or at least 4 other drugs suspected to be effective against the patient's M. tuberculosis isolate and submission of susceptibility testing, if available.
Age Restrictions	5 years of age or older
Prescriber Restrictions	Restricted to infectious diseases and pulmonology
Coverage Duration	26 weeks
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# SIVEXTRO (tedizolid)

## Products Affected

- SIVEXTRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, documentation of a culture and sensitivity showing that the suspected causative agent is susceptible to this medication.
Age Restrictions	12 years of age or older
Prescriber Restrictions	Restricted to infectious diseases
Coverage Duration	6 days
Other Criteria	PA applies to all. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## SKYCLARYS (omaveloxolone)

### Products Affected

- SKYCLARYS

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment
Required Medical Information	Diagnosis of covered use confirmed by genetic testing, submission of liver function testing or Child-Pugh score.
Age Restrictions	16 years of age or older
Prescriber Restrictions	Restricted to neurology and specialists in genetic diseases
Coverage Duration	1 year
Other Criteria	PA applies to all. Documentation of a positive response to therapy will be required for initial reauthorization after the first year. Maintenance of a clinical benefit and attestation that prescriber believes benefits of continuing therapy outweigh the potential risks to the patient will be required for subsequent annual reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# SOFOSBUVIR/VELPATASVIR

## Products Affected

- EPCLUSA ORAL PACKET
- EPCLUSA ORAL TABLET 200-50 MG, 400-100 MG
- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use, laboratory confirmation of hepatitis C virus (HCV) infection, submission of baseline HCV RNA level, documentation of whether cirrhosis is present or not and whether it is compensated or decompensated, confirmation that patients with decompensated cirrhosis will receive concomitant ribavirin therapy unless ribavirin therapy is otherwise clinically not indicated, submission of eGFR (safety and efficacy of sofosbuvir/velpatasvir has not been established in patients with eGFR less than 30 mL/min/1.73 m <sup>2</sup> ), confirmation a test for HBV infection (HBsAg and anti-HBc) was completed.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 weeks
<b>Other Criteria</b>	PA applies to all. For approval of brand Epclusa 400 mg/100 mg, the patient must have tried and failed to have an adequate response to or had an intolerance to sofosbuvir/velpatasvir 400 mg/100 mg.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024



## SOHONOS (palovarotene)

### Products Affected

- SOHONOS

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A4 inhibitors, coadministration with moderate or strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of R206H ACVR1 mutation and pregnancy status for female patients of childbearing potential.
Age Restrictions	For female patients, 8 years of age or older. For male patients, 10 years of age or older.
Prescriber Restrictions	Restricted to orthopedics, rheumatology, and specialists in rare connective tissue diseases
Coverage Duration	1 year
Other Criteria	PA applies to all. Attestation patient is benefitting from treatment and continues to undergo regular pregnancy testing (as necessary for patients of childbearing potential) will be required for all annual reauthorizations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# SOMAVERT (pegvisomant)

## Products Affected

- SOMAVERT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use including attestation that surgery or radiation was not curative or is not an option, submission of baseline IGF-1, submission of baseline liver function testing (LFT) including bilirubin with the requirement liver transaminases either (a) are less than or equal to 3 times the upper limit of normal (ULN), or (b) if greater than 3 times ULN, submission of the cause of liver dysfunction determined through a comprehensive workup.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to endocrinology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. Updated IGF-1 level demonstrating an improvement from baseline, LFT showing liver transaminases below 5 times the ULN, and attestation patient does not have signs or symptoms of liver injury (e.g., jaundice, elevated bilirubin level or bilirubinuria, fatigue, nausea, vomiting, right upper quadrant pain, ascites, unexplained edema, easy bruisability) will be required for initial reauthorization. Updated IGF-1 level demonstrating continued improvement or maintenance of initial effect will be required for subsequent annual reauthorizations.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## SOVALDI (sofosbuvir)

---

### Products Affected

- SOVALDI ORAL PACKET
- SOVALDI ORAL TABLET 200 MG, 400 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, laboratory confirmation of hepatitis C virus (HCV) genotype 1a, 1b, 2, 3, or 4 infection, documentation of whether cirrhosis is present or not and whether or not it is compensated or decompensated, confirmation a test for HBV infection (HBsAg and anti-HBc) was completed.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Criteria for coverage duration will be applied consistent with current AASLD-IDSA guidance.
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## SPRYCEL (dasatinib)

### Products Affected

- SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	Uncorrected hypokalemia, uncorrected hypomagnesemia, coadministration with proton pump inhibitors or H2 receptor antagonists
Required Medical Information	Diagnosis of covered use, submission of serum potassium and magnesium, pregnancy status for female patients of childbearing potential. For adults with resistance or intolerance to prior therapy, documentation of prior therapy.
Age Restrictions	
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## STIVARGA (regorafenib)

---

### Products Affected

- STIVARGA

PA Criteria	Criteria Details
Exclusion Criteria	Severe or uncontrolled hypertension, coadministration with strong CYP3A4 inhibitors or inducers
Required Medical Information	Diagnosis of covered use, submission of previous therapies to match indication, submission of baseline blood pressure reading, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## SUCRAID (sacrosidase)

---

### Products Affected

- SUCRAID

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of laboratory-confirmed congenital sucrase-isomaltase deficiency via differential urinary disaccharide test or measurement of intestinal disaccharides following small bowel biopsy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# SUNITINIB

## Products Affected

- *sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, pregnancy status for female patients of childbearing potential. For gastrointestinal stromal tumor, documentation of prior use of imatinib.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# SUNOSI (solriamfetol)

## Products Affected

- SUNOSI ORAL TABLET 150 MG, 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	End-stage renal disease, administration of non-selective monoamine oxidase inhibitors within 14 days of initiation, serious arrhythmias, unstable cardiovascular disease including uncontrolled hypertension
Required Medical Information	Diagnosis of covered use, submission of baseline blood pressure reading and previous therapies used for diagnosis (see Other Criteria).
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to neurology and sleep medicine
Coverage Duration	1 year
Other Criteria	PA applies to all. This medication will be authorized only if the patient previously tried and had an inadequate clinical response, intolerance, or contraindication to armodafinil or modafinil. Solriamfetol is not indicated to treat the underlying airway obstruction in obstructive sleep apnea and will not be approved for this use.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



## SYMDEKO (tezacaftor/ivacaftor)

---

### Products Affected

- SYMDEKO

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of cystic fibrosis mutation test confirming presence of two copies of the F508del mutation in the CFTR gene or at least one mutation in the CTFR gene responsive to the drug (see section 12.1 of package insert for full list).
Age Restrictions	
Prescriber Restrictions	Restricted to pulmonology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## SYMPROIC (naldemedine)

### Products Affected

- SYMPROIC

PA Criteria	Criteria Details
Exclusion Criteria	Known or suspected gastrointestinal obstruction or increased risk of recurrent obstruction, severe hepatic impairment (Child-Pugh class C)
Required Medical Information	Diagnosis of covered use, documentation patient has been using opioids at a morphine milligram equivalent of at least 30 mg daily for at least 4 weeks prior to initiation, provider attestation that if opioid medication is stopped for any reason, naldemedine will be discontinued.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## SYNAREL (nafarelin)

---

### Products Affected

- SYNAREL

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy/breast-feeding, undiagnosed abnormal vaginal bleeding
Required Medical Information	Diagnosis of covered use, pregnancy status for female patients of childbearing potential.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	For endometriosis, 6 months. For all other diagnoses, 1 year.
Other Criteria	PA applies to all. Re-treatment for endometriosis is not recommended because safety data are not available.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## SYNRIBO (omacetaxine)

### Products Affected

- SYNRIBO

PA Criteria	Criteria Details
Exclusion Criteria	Poor glycemic control
Required Medical Information	Diagnosis of covered use, submission of prior therapies tried and failed, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. For initial approval, patient must have tried and failed or had an intolerance to at least two prior tyrosine kinase inhibitors. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# TABRECTA (capmatinib)

---

## Products Affected

- TABRECTA

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with moderate or strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of MET exon 14 skipping mutation, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# TAFAMIDIS

## Products Affected

- VYNDAMAX
- VYNDAQEL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of transthyretin amyloid cardiomyopathy (ATTRwt or ATTRm) confirmed by one of the following: (1) presence of amyloid deposits on cardiac biopsy, (2) presence of transthyretin precursor protein confirmed on immunohistochemical analysis, scintigraphy, or mass spectrometry, or (3) a TTR genetic mutation plus cardiac involvement defined as thickening of the interseptal ventricular wall, documentation of history of heart failure, with at least one prior hospitalization for heart failure or clinical evidence of heart failure with signs or symptoms of volume overload requiring treatment with a diuretic for improvement.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to cardiology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## TAFINLAR (dabrafenib)

### Products Affected

- TAFINLAR

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP2C8 or CYP3A4 inhibitors
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of BRAF V600E or V600K mutation, pregnancy status for female patients of childbearing potential. For all indications except unresectable/metastatic melanoma with a BRAF V600E mutation, attestation that therapy will be used in combination with trametinib.
Age Restrictions	
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# TAGRISSO (osimertinib)

## Products Affected

- TAGRISSO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of required genetic mutations/deletions for indication, pregnancy status for female patients of childbearing potential. For EGFR T790M mutation-positive NSCLC, documentation that the patient has progressed on or after EGFR TKI therapy.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



# TALZENNA (talazoparib)

## Products Affected

- TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, pregnancy status for female patients of childbearing potential. For breast cancer, submission of test results confirming germline BRCA mutation-positive, human epidermal growth factor receptor 2 (HER2) negative disease. For prostate cancer, submission of test results confirming HRR gene-mutated disease, confirmation talazoparib will be used in combination with enzalutamide.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# TARPEYO (budesonide)

## Products Affected

- TARPEYO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Severe (Child-Pugh class C) hepatic impairment, estimated glomerular filtration rate (eGFR) less than 35 mL/min/1.73 m <sup>2</sup>
<b>Required Medical Information</b>	Diagnosis of primary IgA nephropathy confirmed by biopsy, submission of 24-hour urine protein of at least 1 g/day or 24-hour urine protein-to-creatinine ratio of at least 0.8 g/g, eGFR, liver function testing or Child-Pugh class, attestation patient is stable on a maximally-tolerated renin-angiotensin system antagonist (ACE inhibitor or ARB), documentation patient has progressed on at least one immunosuppressant (e.g., azathioprine, mycophenolate, etc.).
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to immunology and nephrology
<b>Coverage Duration</b>	41 weeks
<b>Other Criteria</b>	PA applies to all. Approval for additional 41-week courses requires documentation of clinically relevant response to therapy, including, but not limited to stabilization or improvement of urine protein-to-creatinine ratio or eGFR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# TASIGNA (nilotinib)

## Products Affected

- TASIGNA

PA Criteria	Criteria Details
Exclusion Criteria	Uncorrected hypokalemia, uncorrected hypomagnesemia, long QT syndrome, coadministration with drugs that prolong the QT interval, proton pump inhibitors, or strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use, submission of Philadelphia chromosome (Ph) status, potassium and magnesium levels.
Age Restrictions	
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# TASIMELTEON

## Products Affected

- *tasimelteon*

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment, coadministration with strong CYP1A2 inhibitors or CYP3A4 inducers
Required Medical Information	Diagnosis of covered use. For Smith-Magenis Syndrome patients only, documentation of genetic testing results confirming diagnosis is required.
Age Restrictions	
Prescriber Restrictions	Restricted to neurology and sleep medicine
Coverage Duration	1 year
Other Criteria	PA applies to all. For non-24-hour sleep-wake disorder, patients are required to be totally blind to match the population in which tasimelteon was studied.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# TAVALISSE (fostamatinib)

## Products Affected

- TAVALISSE ORAL TABLET 100 MG, 150 MG

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of platelet count with a requirement it is less than $30 \times 10^9/L$ or less than $50 \times 10^9/L$ with documented increased risk of bleeding, documentation patient has undergone splenectomy and/or tried and failed two different ITP therapies including systemic corticosteroids, immunoglobulins, danazol, fostamatinib, or cytotoxics/immunosuppressants such as rituximab.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology
Coverage Duration	Initially 12 weeks, then 1 year
Other Criteria	PA applies to all. Documentation of an improvement in platelet count will be required for initial reauthorization after the first 12 weeks. Maintenance of a clinical benefit will be required for subsequent annual reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# TAVNEOS (avacopan)

## Products Affected

- TAVNEOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coadministration with moderate or strong CYP3A4 inducers, active serious infection, chronic active hepatitis B, untreated hepatitis C, uncontrolled autoimmune hepatitis, cirrhosis
<b>Required Medical Information</b>	Diagnosis of covered use (GPA or MPA variant of ANCA-associated vasculitis) and confirmation patient is using rituximab, cyclophosphamide/azathioprine, or another compendium-supported therapy for the treatment of ANCA-associated vasculitis, along with glucocorticoids.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to immunology, nephrology, pulmonology, and rheumatology
<b>Coverage Duration</b>	Initially 6 months, then 1 year
<b>Other Criteria</b>	PA applies to all. Reauthorization requires documentation of clinically relevant response to therapy, including but not limited to disease remission defined using changes in Birmingham Vasculitis Activity Score, a documented reduction in maintenance glucocorticoid dose, or improved or sustained renal function.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## TAZVERIK (tazemetostat)

### Products Affected

- TAZVERIK

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A inhibitors or moderate or strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, pregnancy status for female patients of childbearing potential. For relapsed/refractory follicular lymphoma, documentation (1) of test confirming presence of EZH2 mutation and treatment with at least two prior systemic therapies or (2) patient has no satisfactory alternative treatment option.
Age Restrictions	16 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## TEGSEDI (inotersen)

### Products Affected

- TEGSEDI

PA Criteria	Criteria Details
Exclusion Criteria	Platelet count less than $100 \times 10^9/L$ , urine protein to creatinine ratio (UPCR) above 1,000 mg/g
Required Medical Information	Diagnosis of covered use, submission of genetic testing confirming presence of TTR gene mutation, submission of platelet count and urine protein to creatinine ratio.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. Updated platelet count since the previous authorization will be required for subsequent annual reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



## TEPMETKO (tepotinib)

### Products Affected

- TEPMETKO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of MET exon 14 skipping mutation, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# TERIPARATIDE

## Products Affected

- FORTEO SUBCUTANEOUS SOLUTION PEN-INJECTOR 600 MCG/2.4ML
- *teriparatide (recombinant)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Pre-existing hypercalcemia, underlying hypercalcemic disorder (such as primary hyperparathyroidism), patients with an increased risk of osteosarcoma (such as those with Paget's disease)
<b>Required Medical Information</b>	Diagnosis of covered use where "high risk for fracture" is defined as (1) a history of osteoporotic fracture or (2) multiple risk factors for fracture or (3) patients who have failed or are intolerant of other available osteoporosis therapies, submission of baseline serum calcium, postmenopausal status, documentation that at least one bisphosphonate was tried and failed (or all bisphosphonates, including zoledronic acid, are contraindicated), submission of a value, condition, or past medical history that assesses fracture risk (e.g., DEXA scan results or prior fracture), submission of number of total months of all prior use of parathyroid hormone analogs and parathyroid hormone related peptides.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	2 years unless patient is at high risk for fracture after 2 years of therapy (see Other Criteria)
<b>Other Criteria</b>	PA applies to all. A trial of teriparatide is required for new starts to therapy. Forteo will be approved only if the patient has (1) tried and failed teriparatide or (2) been previously stabilized on Forteo. Updated serum calcium since the previous authorization will be required for reauthorization. Use of parathyroid hormone analogs and/or parathyroid hormone related peptides for more than 2 years during a patient's lifetime is generally not recommended. Requests for continuation of therapy beyond a total of 2 years must be accompanied by evidence that patient remains at high risk for fracture.

3/1/2024

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# TESTOSTERONE REPLACEMENT PRODUCTS

## Products Affected

- ANDRODERM TRANSDERMAL PATCH 24 HOUR (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)
- testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm
- testosterone transdermal solution

PA Criteria	Criteria Details
Exclusion Criteria	History of breast cancer
Required Medical Information	Diagnosis of covered use, submission of serum testosterone level, documentation that patient has been evaluated for the presence of prostate cancer prior to initiation of therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. Documentation of clinically relevant response to therapy (including, but not limited to submission of updated serum testosterone level) will be required for subsequent reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## TIBSOVO (ivosidenib)

---

### Products Affected

- TIBSOVO

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of IDH1 mutation. For cholangiocarcinoma, submission of previous therapies.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# TOLVAPTAN (HYPONATREMIA)

## Products Affected

- *tolvaptan*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Underlying liver disease, need to raise serum sodium acutely, inability to sense or respond to thirst, hypovolemia, anuria, coadministration with strong CYP3A inhibitors or inducers or desmopressin
<b>Required Medical Information</b>	Diagnosis of covered use, submission of evidence of clinically significant hyponatremia, defined as (1) serum sodium less than 125 mEq/L or (2) serum sodium less than 135 mEq/L that is symptomatic and has resisted correction with fluid restriction.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	30 days
<b>Other Criteria</b>	PA applies to all. Treatment should be initiated in a setting where serum sodium can be monitored closely. Treatment is limited to 30 days to prevent liver injury. This formulation of tolvaptan will not be approved for autosomal dominant polycystic kidney disease (ADPKD) because the tolvaptan formulation approved for ADPKD has a mandatory REMS program.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# TOPICAL PSORIASIS TREATMENTS

## Products Affected

- VTAMA
- ZORYVE EXTERNAL CREAM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use, submission of percent body surface area affected (with a requirement BSA affected is less than or equal to 20 percent), documentation patient either (1) has tried and failed, had an incomplete response to, had an intolerance to, or has contraindications to at least one Class/Group 3 high potency or stronger topical corticosteroid and at least one of the following other topical agents: tazarotene or a vitamin D analog such as calcipotriene or calcitriol, or (2) patient is currently using a systemic medication (biologic or otherwise) to manage psoriasis.
<b>Age Restrictions</b>	For Vtama, 18 years of age or older. For Zoryve, 6 years of age or older.
<b>Prescriber Restrictions</b>	For Vtama, restricted to dermatology. For Zoryve, PA not required for dermatology.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. Documentation of a positive response to therapy will be required for reauthorization.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## TRIKAFTA (elexacaftor/tezacaftor/ivacaftor)

### Products Affected

- TRIKAFTA ORAL TABLET THERAPY PACK 100-50-75 & 150 MG, 50-25-37.5 & 75 MG
- TRIKAFTA ORAL THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment, coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of cystic fibrosis mutation test confirming presence of at least one mutation in the CFTR gene responsive to the drug (see section 12.1 of package insert for full list) or a mutation that is responsive based on in vitro data.
Age Restrictions	
Prescriber Restrictions	Restricted to pulmonology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



## TRUQAP (capivasertib)

### Products Affected

- TRUQAP

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with moderate or strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use, submission of pregnancy status for female patients of childbearing potential, genetic tumor testing showing that the primary tumor type is HR-positive, HER2-negative, submission of test confirming presence of PIK3CA, AKT1, and/or PTEN mutation, submission of previous systemic treatment(s) tried to match the indication, and confirmation drug will be given with fulvestrant. In patients with a PIK3CA mutation and no AKT1 and/or PTEN mutation, documentation patient has tried and failed, had an intolerance to, or has a contraindication to alpelisib.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# TUKYSA (tucatinib)

## Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy, coadministration with strong CYP3A inducers or moderate CYP2C8 inducers
Required Medical Information	Diagnosis of covered use, submission of genetic tumor testing showing that the primary tumor type is HER2-positive, submission of previous systemic treatment including prior HER2-directed therapy, pregnancy status for female patients of childbearing potential. For metastatic colon cancer, documentation tumor is RAS wild-type.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# TURALIO (pexidartinib)

## Products Affected

- TURALIO

PA Criteria	Criteria Details
Exclusion Criteria	Active liver or biliary tract disease (including increased ALP), pre-existing increased serum transaminases, total or direct bilirubin greater than the upper limit of normal, coadministration with other hepatotoxic medications, strong CYP3A inducers, or proton pump inhibitors
Required Medical Information	Diagnosis of covered use (and surgical intervention is not possible or practical), submission of serum transaminases, total and direct bilirubin, and ALP, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# TYMLOS (abaloparatide)

## Products Affected

- TYMLOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Female patients of childbearing potential, pre-existing hypercalcemia, underlying hypercalcemic disorder (such as primary hyperparathyroidism), patients with an increased risk of osteosarcoma (such as those with Paget's disease)
<b>Required Medical Information</b>	Diagnosis of covered use where "high risk for fracture" is defined as (1) a history of osteoporotic fracture or (2) multiple risk factors for fracture or (3) patients who have failed or are intolerant of other available osteoporosis therapies, submission of baseline serum calcium, documentation that at least one bisphosphonate was tried and failed (or all bisphosphonates, including zoledronic acid, are contraindicated), submission of a value, condition, or past medical history that assesses fracture risk (e.g., DEXA scan results or prior fracture), submission of number of total months of all prior use of parathyroid hormone analogs and parathyroid hormone related peptides. For females, attestation of postmenopausal status. For males not at high risk for fracture, documentation of all other treatments tried and failed or intolerant to or contraindicated.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	2 years maximum dependent on patient's prior use of all PTH analogs and PTH-related peptides
<b>Other Criteria</b>	PA applies to all. Use of parathyroid hormone analogs and/or parathyroid hormone related peptides for more than 2 years during a patient's lifetime is not recommended. Requests for continuation of therapy beyond a total of 2 years must be accompanied by evidence that patient remains at high risk for fracture.

3/1/2024

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## UPTRAVI (selexipag)

### Products Affected

- UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- UPTRAVI TITRATION

PA Criteria	Criteria Details
Exclusion Criteria	Severe (Child-Pugh class C) hepatic impairment, coadministration with strong CYP2C8 inhibitors
Required Medical Information	Diagnosis of covered use.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to cardiology and pulmonology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# UTERINE FIBROID ORAL THERAPIES

## Products Affected

- MYFEMBREE
- ORIAHNN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Pregnancy, known liver impairment or disease, known osteoporosis, undiagnosed abnormal uterine bleeding, women who are at increased risk of, have a history of, or currently have thrombotic or thromboembolic disorders (including women over 35 years of age who smoke and women with uncontrolled hypertension), current/history of breast cancer or other hormone-sensitive cancer
<b>Required Medical Information</b>	Diagnosis of covered use, attestation patient is premenopausal, submission of baseline blood pressure, pregnancy status for female patients of childbearing potential.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Restricted to endocrinology and gynecology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all. Use of this drug for more than 2 years increases risk of bone loss and requests for therapy for more than 2 years will not be approved.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## VALCHLOR (mechlorethamine)

---

### Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	Use as initial therapy
Required Medical Information	Diagnosis of covered use, submission of previous skin-directed therapy.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to dermatology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



## VANFLYTA (quizartinib)

### Products Affected

- VANFLYTA

PA Criteria	Criteria Details
Exclusion Criteria	Uncorrected hypokalemia or hypomagnesemia, QTcF interval greater than 450 msec at treatment initiation, coadministration with moderate or strong CYP3A inducers
Required Medical Information	Diagnosis of covered use including submission of test confirming presence of FLT3 mutation, submission of QTcF interval, baseline serum potassium and magnesium levels, and pregnancy status for female patients of childbearing potential, attestation patient does not have history of ventricular arrhythmias or torsades de pointes.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## VENCLEXTA (venetoclax)

### Products Affected

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with moderate or strong CYP3A inducers. For CLL/SLL, coadministration with strong CYP3A inhibitors at treatment initiation and initial dosage titration.
Required Medical Information	Diagnosis of covered use, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## VENTAVIS (iloprost)

---

### Products Affected

- VENTAVIS

PA Criteria	Criteria Details
Exclusion Criteria	Systolic blood pressure below 85 mmHg
Required Medical Information	Diagnosis of covered use, submission of baseline systolic blood pressure.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to cardiology and pulmonology
Coverage Duration	1 year
Other Criteria	This medication is covered as a Part B benefit except for enrollees residing in a long-term care facility. PA applies to new starts only when covered as a Part D benefit.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## VEOZAH (fezolinetant)

### Products Affected

- VEOZAH

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coadministration with CYP1A2 inhibitors, severe renal impairment or end-stage renal disease, known cirrhosis
<b>Required Medical Information</b>	Diagnosis of covered use, submission of creatinine clearance (or serum creatinine, actual body weight, and height to calculate estimated creatinine clearance), documentation patient has tried and had an inadequate response to at least one prior systemic hormone therapy or FDA-approved or compendia-supported non-hormonal therapy (e.g., SSRI, SNRI, clonidine, gabapentin, etc.) for the treatment of vasomotor symptoms due to menopause.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

# VERQUVO (vericiguat)

## Products Affected

- VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of another soluble guanylate cyclase (sGC) stimulator or a phosphodiesterase-5 (PDE-5) inhibitor
Required Medical Information	Diagnosis, including either hospitalization for heart failure with reduced ejection fraction (HFrEF) within the previous 6 months or outpatient IV diuretic use within the previous 3 months, submission of left ventricular ejection fraction and pregnancy status for female patients of childbearing potential. Prescribers are also required to submit current regimen for the treatment of HFrEF, which must include (1) a renin-angiotensin system (RAS) inhibitor (ACE inhibitor, ARB, or sacubitril/valsartan), (2) a beta-blocker (BB), and (3) a mineralocorticoid receptor antagonist (MRA), each at maximally-tolerated doses. If any of these three therapies are not currently being used, prescriber is required to submit documentation as to why (e.g., contraindications, intolerances, etc.). Using the recommended dose of each therapeutic component to treat HFrEF is required. If the doses of any of these three components have not been optimized to the recommended dose to treat HFrEF, the prescriber is required to submit documentation as to why (e.g., intolerances, physiologic parameters, etc.). If the patient is using a BB not indicated for HFrEF, the patient will be required to switch to one of the three FDA-approved BBs for HFrEF (bisoprolol, carvedilol, or metoprolol succinate).
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All FDA-approved Indications.

3/1/2024

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## VERZENIO (abemaciclib)

---

### Products Affected

- VERZENIO

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with moderate or strong CYP3A4 inducers or ketoconazole
Required Medical Information	Diagnosis of covered use, submission of genetic tumor testing showing that the primary tumor type is HR-positive, HER2-negative, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

# VIBERZI (eluxadoline)

## Products Affected

- VIBERZI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Prior cholecystectomy, known or suspected biliary duct obstruction, known or suspected sphincter of Oddi disease or dysfunction, alcoholism, alcohol abuse, alcohol addiction, or patients who drink more than 3 alcoholic beverages/day, history of pancreatitis, structural diseases of pancreas including known or suspected pancreatic duct obstruction, severe hepatic impairment (Child-Pugh class C), severe constipation or sequelae from constipation, known or suspected mechanical gastrointestinal obstruction
<b>Required Medical Information</b>	Diagnosis of covered use.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to gastroenterology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024



## VIJOICE (alpelisib)

### Products Affected

- VIJOICE ORAL TABLET THERAPY PACK 125 MG, 200 & 50 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use including at least one target lesion on imaging with requesting provider attestation patient has severe or life-threatening disease, submission of test confirming presence of mutation in PIK3CA gene, pregnancy status for female patients of childbearing potential.
Age Restrictions	
Prescriber Restrictions	Restricted to specialists in genetic diseases or inborn errors of metabolism
Coverage Duration	Initially 6 months, then 1 year
Other Criteria	PA applies to all. Submission of objective documentation of a clinical benefit (e.g., reductions in target lesion size, pain, vascular malformations, limb enlargements, etc.) in the absence of unacceptable toxicity will be required for subsequent reauthorizations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## VITRAKVI (larotrectinib)

### Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of evidence of a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation and attestation tumor is metastatic or surgical resection/other systemic therapies are unsatisfactory treatment options, pregnancy status for female patients of childbearing potential.
Age Restrictions	
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## VIVJOA (oteseconazole)

### Products Affected

- VIVJOA

PA Criteria	Criteria Details
Exclusion Criteria	Women of reproductive potential
Required Medical Information	Diagnosis of covered use, including attestation patient has had at least three episodes of vulvovaginal candidiasis in the previous 12 months, attestation patient is either (a) postmenopausal or (b) infertile.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 weeks
Other Criteria	PA applies to all.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## VIZIMPRO (dacomitinib)

---

### Products Affected

- VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with a proton pump inhibitor
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of EGFR exon 19 deletion or exon 21 L858R substitution mutation, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## VMAT2 INHIBITORS

### Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG
- AUSTEDO PATIENT TITRATION KIT
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 24 MG, 6 MG
- AUSTEDO XR PATIENT TITRATION
- INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG
- INGREZZA ORAL CAPSULE THERAPY PACK
- *tetrabenazine oral tablet 12.5 mg, 25 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Congenital long QT syndrome or a history of cardiac arrhythmia associated with a prolonged QT interval, coadministration with monoamine oxidase inhibitors. For tetrabenazine and Austedo, actively suicidal or untreated/undertreated depression, hepatic impairment. For Ingrezza, coadministration with strong CYP3A4 inducers.
<b>Required Medical Information</b>	Diagnosis of covered use.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to neurology and psychiatry
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to all.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## VONJO (pacritinib)

### Products Affected

- VONJO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Moderate or severe (Child-Pugh class B or C) hepatic impairment, estimated glomerular filtration rate (eGFR) less than 30 mL/min, QTc interval greater than 480 msec at baseline, uncorrected hypokalemia, coadministration with strong CYP3A4 inducers or strong CYP3A4 inhibitors
<b>Required Medical Information</b>	Diagnosis of covered use, submission of platelet count, serum potassium level, eGFR, and QTc interval, documentation from a physical exam patient has splenomegaly.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to hematology or oncology
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	PA applies to new starts only.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## VOQUEZNA (vonoprazan)

### Products Affected

- VOQUEZNA ORAL TABLET 10 MG, 20 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of (1) erosive esophagitis confirmed by endoscopy or (2) Helicobacter pylori infection. For erosive esophagitis only, documentation of treatment failure with at least one proton pump inhibitor or a contraindication to the proton pump inhibitor class. For Helicobacter pylori infection only, attestation patient will be administering with amoxicillin or a combination of amoxicillin and clarithromycin.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	32 weeks
Other Criteria	PA applies to all. This product is not approved for heartburn or gastroesophageal reflux disease (GERD) without evidence of erosive esophagitis and will not be authorized for these uses.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## VOSEVI (sofosbuvir, velpatasvir, voxilaprevir)

### Products Affected

- VOSEVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Moderate or severe hepatic impairment, coadministration with rifampin or drugs that are strong P-glycoprotein inducers or moderate to strong CYP2B6, CYP2C8, or CYP3A4 inducers
<b>Required Medical Information</b>	Diagnosis of covered use, laboratory confirmation of hepatitis C virus (HCV) and genotype, documentation of whether cirrhosis is present or not and whether or not it is compensated or decompensated, submission of previous treatment regimen, confirmation a test for HBV infection (HBsAg and anti-HBc) was completed.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 weeks
<b>Other Criteria</b>	PA applies to all.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024



## VOTRIENT (pazopanib)

### Products Affected

- *pazopanib hcl*

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment, uncontrolled hypertension, uncorrected hypokalemia, hypocalcemia, or hypomagnesemia, coadministration with strong CYP3A4 inducers or drugs that can prolong the QT interval
Required Medical Information	Diagnosis of covered use, submission of baseline blood pressure, serum potassium, calcium, and magnesium, pregnancy status for female patients of childbearing potential. For soft tissue sarcoma, submission of previous chemotherapy regimen(s).
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## VOWST (fecal microbiota, live-jslm)

### Products Affected

- VOWST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use with the requirement patient is being treated after at least 2 recurrent (3 total) Clostridioides difficile infections (confirmation of pathogen with stool test or other confirmatory test), submission of time of last planned dose of antibiotic for latest recurrent C. difficile infection and attestation patient will be using a bowel cleanse the evening prior to starting Vowst, confirmation patient has had prior therapy with bezlotoxumab or has a contraindication to its use, confirmation patient has had prior therapy with either fecal microbiota, live-jslm rectal suspension or a fecal microbiota transplant from a reputable source or has a contraindication to use of a fecal microbiota transplant.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 course (3 days)
<b>Other Criteria</b>	PA applies to all.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## VRAYLAR (cariprazine)

---

### Products Affected

- VRAYLAR ORAL CAPSULE
- VRAYLAR ORAL CAPSULE THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	Dementia-related psychosis, severe hepatic impairment, severe renal impairment (creatinine clearance less than 30 mL/min), coadministration with CYP3A4 inducers
Required Medical Information	Diagnosis of covered use.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to neurology and psychiatry
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## WAKIX (pitolisant)

### Products Affected

- WAKIX ORAL TABLET 17.8 MG, 4.45 MG

PA Criteria	Criteria Details
Exclusion Criteria	Severe hepatic impairment, end-stage renal disease, known QT interval prolongation, symptomatic bradycardia, uncorrected hypokalemia or hypomagnesemia, coadministration with medications that prolong the QT interval
Required Medical Information	Diagnosis of covered use, submission of serum potassium and magnesium and previous therapies used for diagnosis (see Other Criteria).
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to neurology and sleep medicine
Coverage Duration	1 year
Other Criteria	PA applies to all. For excessive daytime sleepiness associated with narcolepsy, pitolisant will be authorized only if the patient previously tried and had an inadequate clinical response, an intolerance, or contraindication to (1) armodafinil or modafinil and (2) solriamfetol. Updated serum potassium and magnesium since the previous authorization will be required for subsequent annual reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## WELIREG (belzutifan)

### Products Affected

- WELIREG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of pregnancy status for female patients of childbearing potential. For von Hippel-Lindau (VHL) disease, confirmation of a germline VHL alteration and attestation patient does not require immediate surgery. For advanced renal cell carcinoma, confirmation patient was previously treated with a programmed death receptor-1 or programmed death-ligand 1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## XALKORI (crizotinib)

### Products Affected

- XALKORI

PA Criteria	Criteria Details
Exclusion Criteria	Congenital long QT syndrome, coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of test confirming tumor is ALK or ROS1-positive, pregnancy status for female patients of childbearing potential.
Age Restrictions	For ALK-positive systemic anaplastic large cell lymphoma only, 1 year of age to 21 years of age
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## XERMELO (telotristat)

### Products Affected

- XERMELO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, documentation patient has been on at least 12 weeks of prior somatostatin analog therapy.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	12 weeks
Other Criteria	PA applies to all. Continuation of therapy requires that symptoms have stabilized or improved and that the patient has not experienced episodes of severe constipation.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## XGEVA (denosumab)

### Products Affected

- XGEVA

PA Criteria	Criteria Details
Exclusion Criteria	Hypocalcemia
Required Medical Information	Diagnosis of covered use, submission of serum calcium level, pregnancy status for female patients of childbearing potential.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to new starts only. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



# XOLAIR (omalizumab)

## Products Affected

- XOLAIR

PA Criteria	Criteria Details
Exclusion Criteria	Weight greater than 150 kg
Required Medical Information	Diagnosis of covered use. For asthma, documentation that patient's symptoms are poorly controlled with at least a 30-day trial of inhaled corticosteroids plus at least one of the following: a long-acting beta-agonist, long-acting muscarinic antagonist, leukotriene inhibitor, or theophylline, submission of pre-treatment serum IgE level between 30 and 700 IU/mL in patients 12 years of age and older, documentation patient has a pre-bronchodilator FEV1 less than 80 percent predicted, positive skin test result or demonstrated in vitro reactivity (RAST test) to a perennial aeroallergen, frequency of daily and nighttime symptoms and exacerbations, and effect of exacerbations on activity. For chronic spontaneous urticaria, documentation that the patient continues to experience severe itching and hives despite the use of an H1 antihistamine at an approved dose for at least 30 days. For nasal polyps, documentation of treatment with an intranasal corticosteroid for at least 30 days, a contraindication to the use of intranasal corticosteroids, or why therapy is not otherwise advisable, and if the patient does not have an intolerance or contraindication to intranasal corticosteroids, attestation omalizumab will be used in addition to this therapy.
Age Restrictions	6 years of age or older
Prescriber Restrictions	Restricted to allergy, dermatology, immunology, otolaryngology/otorhinolaryngology, and pulmonology
Coverage Duration	Initially 6 months, then 1 year

3/1/2024

PA Criteria	Criteria Details
<b>Other Criteria</b>	PA applies to all. Submission of objective documentation of symptomatic improvement (i.e., a reduction in asthma exacerbations) will be required for subsequent reauthorizations. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

3/1/2024

## XOSPATA (gilteritinib)

---

### Products Affected

- XOSPATA

PA Criteria	Criteria Details
Exclusion Criteria	Uncorrected hypokalemia or hypomagnesemia, coadministration with dual strong CYP3A/P-glycoprotein inducers
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of FLT3 mutation, serum potassium and magnesium, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## XPOVIO (selinexor)

### Products Affected

- XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG
- XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, documentation of treatment failure with or intolerance to all prior therapies to match the indication, submission of pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## XURIDEN (uridine triacetate)

### Products Affected

- XURIDEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, submission of baseline CBC including neutrophil count and mean corpuscular volume, baseline urine orotic acid level.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all. Updated urine orotic acid level and CBC including neutrophil count and mean corpuscular volume since the previous authorization will be required for subsequent annual reauthorizations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ZEJULA (niraparib)

### Products Affected

- ZEJULA ORAL CAPSULE
- ZEJULA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, pregnancy status for female patients of childbearing potential, documentation of response to platinum-based chemotherapy. For germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, submission of test confirming presence of deleterious BRCA mutation.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ZERBAXA (ceftolozane/tazobactam)

### Products Affected

- ZERBAXA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use, documentation of a culture and sensitivity showing that the suspected causative agent is susceptible to this medication. For complicated intra-abdominal infections, confirmation patient will receive concurrent metronidazole therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	For UTI including pyelonephritis, 7 days. For all other FDA-approved indications, 14 days.
Other Criteria	PA applies to all. A description of how the drug will be used and/or obtained may be required to determine whether it will be covered under Medicare Part B or Part D. If the medication will be self-administered after proper training or the provider agrees to have the medication filled at a pharmacy and delivered to the office by the patient for provider administration, it may be covered under Part D. If these conditions are not satisfied this medication may be covered under Part B.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ZILBRYSQ (zilucoplan)

### Products Affected

- ZILBRYSQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of covered use including confirmation via a history of abnormal neuromuscular transmission tests or improvement with acetylcholinesterase inhibitors and a positive serological test for AChR-Ab, submission of MGFA classification with a requirement the patient has class II-IV MG and baseline MG-ADL score with a requirement the score is at least 6, attestation patient will not concurrently use rituximab or eculizumab, confirmation patient has failed to respond to at least one drug in two of the following three drug groups: (1) acetylcholinesterase inhibitors (e.g., pyridostigmine), (2) corticosteroids (e.g., prednisone), or (3) non-steroidal immunosuppressive therapies (e.g., azathioprine, cyclosporine, methotrexate, mycophenolate), attestation patient has received meningococcal vaccination against subgroups A, B, C, W, and Y and does not have an unresolved N. meningitidis infection.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Restricted to neurology
<b>Coverage Duration</b>	Initially 6 months, then 1 year
<b>Other Criteria</b>	PA applies to all. Documentation of any positive response to therapy will be required for initial reauthorization after the first 6 months. Maintenance of a clinical benefit, attestation the patient is up to date on all vaccinations, and attestation that prescriber believes benefits of continuing therapy outweigh the potential risks to the patient will be required for subsequent annual reauthorizations.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

3/1/2024



PA Criteria	Criteria Details
Part B Prerequisite	No

3/1/2024

## ZOKINVY (lonafarnib)

---

### Products Affected

- ZOKINVY ORAL CAPSULE 50 MG, 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	Body surface area less than 0.39 m <sup>2</sup> , coadministration with moderate or strong CYP3A inhibitors or inducers, midazolam, atorvastatin, lovastatin, or simvastatin
Required Medical Information	Diagnosis of covered use including results of genetic testing supporting diagnosis, pregnancy status for female patients of childbearing potential.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to all.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ZONTIVITY (vorapaxar)

---

### Products Affected

- ZONTIVITY

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy, history of stroke, transient ischemic attack, or intracranial hemorrhage, active pathological bleeding, severe hepatic impairment, coadministration with strong CYP3A inhibitors or inducers
Required Medical Information	Diagnosis of covered use, confirmation that patient has not had prior stroke, transient ischemic attack, or intracranial hemorrhage, attestation therapy will be coadministered with aspirin and/or clopidogrel.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ZORBTIVE (somatropin)

---

### Products Affected

- ZORBTIVE

PA Criteria	Criteria Details
Exclusion Criteria	Active malignancy, acute critical illness, active proliferative or severe non-proliferative diabetic retinopathy
Required Medical Information	Diagnosis of covered use.
Age Restrictions	18 years of age or older
Prescriber Restrictions	
Coverage Duration	4 weeks
Other Criteria	PA applies to all. Zorbtive is indicated only for the treatment of short bowel syndrome and uses outside of this indication will not be approved.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ZTALMY (ganaxolone)

### Products Affected

- ZTALMY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of covered use confirmed by genetic testing including either (a) a CDKL5 gene that is pathogenic or likely to be pathogenic or (b) CDKL5 deficiency, documentation of failure of at least two previous anticonvulsant therapies, submission of baseline monthly major motor seizure (defined as bilateral tonic, generalized tonic-clonic, bilateral clonic, atonic, or focal to bilateral tonic-clonic seizure) frequency, with the requirement that the frequency is at least 16 major motor seizures per month.
Age Restrictions	
Prescriber Restrictions	Restricted to neurology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ZURZUVAE (zuranolone)

### Products Affected

- ZURZUVAE

PA Criteria	Criteria Details
Exclusion Criteria	Current pregnancy, bipolar disorder, schizophrenia, or schizoaffective disorder, coadministration with strong CYP3A4 inducers
Required Medical Information	Diagnosis of covered use (with provider attestation of moderate to severe postpartum depression), attestation patient is within 12 months postpartum.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to gynecology, obstetrics, and psychiatry
Coverage Duration	14 days
Other Criteria	PA applies to all. As there are no safety or efficacy data beyond one 14-day course for postpartum depression, only one 14-day course will be allowed per plan year.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ZYDELIG (idelalisib)

### Products Affected

- ZYDELIG

PA Criteria	Criteria Details
Exclusion Criteria	History of serious hypersensitivity reactions, including toxic epidermal necrolysis with any drug, coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, attestation therapy will be coadministered with rituximab, documentation of at least one previous line of systemic therapy, submission of pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to hematology and oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024

## ZYKADIA (ceritinib)

---

### Products Affected

- ZYKADIA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	Coadministration with strong CYP3A inducers
Required Medical Information	Diagnosis of covered use, submission of test confirming presence of ALK-positive tumor, pregnancy status for female patients of childbearing potential.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Restricted to oncology
Coverage Duration	1 year
Other Criteria	PA applies to new starts only.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

3/1/2024



3/1/2024

## INDEX

ABILIFY MYCITE MAINTENANCE KIT ORAL TABLET THERAPY PACK 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG .....	1	AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG .....	16
ABILIFY MYCITE STARTER KIT ORAL TABLET THERAPY PACK 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG .....	1	BAFIERTAM .....	82
<i>abiraterone acetate oral tablet 250 mg</i> .....	191	BALVERSA .....	17
ACTEMRA ACTPEN .....	23	BENLYSTA SUBCUTANEOUS .....	20
ACTEMRA SUBCUTANEOUS .....	23	BERINERT .....	89
ACTIMMUNE .....	2	BESREMI .....	21
ADEMPAS .....	3	<i>bexarotene external</i> .....	22
AIMOVIG SUBCUTANEOUS SOLUTION		BIVIGAM INTRAVENOUS SOLUTION 5 GM/50ML .....	95
AUTO-INJECTOR 140 MG/ML, 70 MG/ML ....	40	<i>bosentan oral tablet 125 mg, 62.5 mg</i> .....	65
AJOVY .....	40	BOSULIF ORAL CAPSULE 100 MG, 50 MG ....	25
AKEEGA .....	4	BOSULIF ORAL TABLET .....	25
ALECENSA .....	5	BRAFTOVI ORAL CAPSULE 75 MG .....	26
ALUNBRIG .....	7	BRONCHITOL .....	27
<i>alyq</i> .....	176	BRUKINSA .....	28
<i>ambrisentan oral tablet 10 mg, 5 mg</i> .....	65	<i>butalbital-acetaminophen oral tablet 50- 325 mg</i> .....	29
AMVUTTRA .....	9	<i>butalbital-apap-caff-cod</i> .....	29
ANDRODERM TRANSDERMAL PATCH 24 HOUR .....	243	<i>butalbital-apap-caffeine oral capsule</i> .....	29
<i>apomorphine hcl subcutaneous</i> .....	174	<i>butalbital-apap-caffeine oral tablet 50- 325-40 mg</i> .....	29
ARALAST NP INTRAVENOUS SOLUTION		<i>butalbital-asa-caff-codeine</i> .....	29
RECONSTITUTED 1000 MG, 500 MG .....	6	<i>butalbital-aspirin-caffeine oral capsule</i> .....	29
ARANESP (ALBUMIN FREE) INJECTION		BYLVAY .....	30
SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML .....	70	BYLVAY (PELLETS) .....	30
ARANESP (ALBUMIN FREE) INJECTION		CABLIVI .....	31
SOLUTION PREFILLED SYRINGE .....	70	CABOMETYX .....	32
ARCALYST .....	11	CALQUENCE .....	33
ARIKAYCE .....	12	CAMZYOS .....	34
ASCOMP-CODEINE .....	29	CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG .....	36
AUGTYRO .....	13	CAPRELSA .....	37
AURYXIA .....	14	<i>carbinoxamine maleate oral solution</i> .....	79
AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG .....	268	<i>carbinoxamine maleate oral tablet 4 mg</i> .....	79
AUSTEDO PATIENT TITRATION KIT .....	268	<i>carglumic acid oral tablet soluble</i> .....	38
AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 24 MG, 6 MG ...	268	CERDELGA .....	39
AUSTEDO XR PATIENT TITRATION .....	268	CHENODAL .....	42
AUVELITY .....	15	CHOLBAM .....	43
		<i>cilostazol</i> .....	139
		CIMZIA STARTER KIT SUBCUTANEOUS PREFILLED SYRINGE KIT .....	23
		CIMZIA SUBCUTANEOUS KIT 2 X 200 MG ....	23

CIMZIA SUBCUTANEOUS PREFILLED SYRINGE KIT .....	23	<i>erlotinib hcl</i> .....	69
<i>clemastine fumarate oral tablet 2.68 mg</i> .....	79	<i>eszopiclone</i> .....	208
COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG .....	44	<i>everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg</i> .....	71
COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG .....	44	<i>everolimus oral tablet soluble</i> .....	71
COMETRIQ (60 MG DAILY DOSE) .....	44	EVRYSDI .....	72
COPIKTRA ORAL CAPSULE 15 MG, 25 MG .....	45	EXKIVITY .....	73
CORLANOR .....	184	<i>ezetimibe-simvastatin oral tablet 10-80 mg</i> .....	211
CORTROPHIN .....	46	<i>fentanyl citrate buccal</i> .....	74
COTELLIC .....	47	FERRIPROX ORAL SOLUTION .....	53
CRESEMBA ORAL CAPSULE 186 MG .....	48	FILSPARI .....	76
CUVITRU .....	95	FINTEPLA .....	77
<i>cypheptadine hcl oral</i> .....	79	FIRDAPSE .....	78
CYSTADROPS .....	49	FLEBOGAMMA DIF .....	95
CYSTARAN .....	49	FORTEO SUBCUTANEOUS SOLUTION PEN-INJECTOR 600 MCG/2.4ML .....	241
<i>dalfampridine er</i> .....	50	FOTIVDA .....	80
DAURISMO ORAL TABLET 100 MG, 25 MG ..	51	FRUZAQLA ORAL CAPSULE 1 MG, 5 MG .....	81
DAYVIGO ORAL TABLET 10 MG, 5 MG .....	165	GALAFOLD .....	83
<i>deferasirox oral tablet</i> .....	52	GAMMAGARD .....	95
<i>deferasirox oral tablet soluble</i> .....	52	GAMMAGARD S/D LESS IGA .....	95
<i>deferiprone</i> .....	53	GAMMAKED INJECTION SOLUTION 1 GM/10ML, 10 GM/100ML, 20 GM/200ML, 5 GM/50ML .....	95
DIACOMIT .....	54	GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 20 GM/400ML, 5 GM/100ML, 5 GM/50ML .....	95
<i>dichlorphenamide</i> .....	55	GAMUNEX-C .....	95
<i>diclofenac epolamine external</i> .....	56	GATTEX .....	84
<i>diclofenac sodium external gel 3 %</i> .....	184	GAVRETO .....	85
<i>digoxin oral tablet 250 mcg</i> .....	57	<i>gefitinib</i> .....	86
<i>diphenhydramine hcl oral elixir</i> .....	79	GILOTRIF .....	87
DOPTELET ORAL TABLET 20 MG .....	58	GLASSIA .....	6
<i>dronabinol</i> .....	59	HAEGARDA .....	90
DUOBRII .....	60	HARVONI ORAL PACKET 45-200 MG .....	118
DUPIXENT .....	61	HARVONI ORAL TABLET 90-400 MG .....	118
EGRIFTA SV .....	63	HIZENTRA SUBCUTANEOUS SOLUTION 1 GM/5ML, 10 GM/50ML, 2 GM/10ML, 4 GM/20ML .....	95
EMGALITY .....	40	HIZENTRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE .....	95
EMGALITY (300 MG DOSE) .....	40	<i>hydroxyzine hcl oral tablet</i> .....	79
ENDARI .....	64		
ENSPRYNG .....	66		
EPCLUSA ORAL PACKET .....	215		
EPCLUSA ORAL TABLET 200-50 MG, 400-100 MG .....	215		
EPIDIOLEX .....	67		
ERIVEDGE .....	68		
ERLEADA .....	191		

<i>hydroxyzine pamoate oral</i> .....	79	<i>lapatinib ditosylate</i> .....	117
IBRANCE.....	91	<i>ledipasvir-sofosbuvir</i> .....	118
<i>icatibant acetate subcutaneous solution</i>		<i>lenalidomide</i> .....	119
<i>prefilled syringe</i> .....	89	LENVIMA (10 MG DAILY DOSE).....	120
ICLUSIG.....	92	LENVIMA (12 MG DAILY DOSE).....	120
IDHIFA.....	93	LENVIMA (14 MG DAILY DOSE).....	120
IMBRUVICA.....	94	LENVIMA (18 MG DAILY DOSE).....	120
INBRIJA.....	174	LENVIMA (20 MG DAILY DOSE).....	120
INCRELEX.....	138	LENVIMA (24 MG DAILY DOSE).....	120
INGREZZA ORAL CAPSULE 40 MG, 60 MG,		LENVIMA (4 MG DAILY DOSE).....	120
80 MG.....	268	LENVIMA (8 MG DAILY DOSE).....	120
INGREZZA ORAL CAPSULE THERAPY PACK.	268	LEUKINE INJECTION SOLUTION	
INLYTA.....	97	RECONSTITUTED.....	121
INQOVI.....	98	<i>lidocaine external patch 5 %</i> .....	122
INREBIC.....	99	LIVMARLI.....	123
INVEGA HAFYERA.....	101	LIVTENCITY.....	124
INVEGA TRINZA INTRAMUSCULAR		LODOCO.....	125
SUSPENSION PREFILLED SYRINGE 273		LONSURF.....	127
MG/0.88ML, 410 MG/1.32ML, 546		LORBRENA ORAL TABLET 100 MG, 25 MG.	128
MG/1.75ML, 819 MG/2.63ML.....	101	LUMAKRAS.....	129
ISTURISA.....	102	LUPKYNIS.....	130
<i>itraconazole oral</i> .....	139	LYBALVI.....	132
IWILFIN.....	103	LYNPARZA ORAL TABLET.....	133
JAKAFI.....	104	LYTGOBI (12 MG DAILY DOSE).....	134
JAYPIRCA.....	105	LYTGOBI (16 MG DAILY DOSE).....	134
JOENJA.....	106	LYTGOBI (20 MG DAILY DOSE).....	134
JUXTAPID ORAL CAPSULE 10 MG, 20 MG,		MAVENCLAD (10 TABS).....	135
30 MG, 5 MG.....	107	MAVENCLAD (4 TABS).....	135
JYNARQUE.....	109	MAVENCLAD (5 TABS).....	135
KALYDECO.....	110	MAVENCLAD (6 TABS).....	135
KERENDIA.....	111	MAVENCLAD (7 TABS).....	135
<i>ketoconazole oral</i> .....	112	MAVENCLAD (8 TABS).....	135
KEVEYIS.....	55	MAVENCLAD (9 TABS).....	135
KINERET SUBCUTANEOUS SOLUTION		MAVYRET.....	137
PREFILLED SYRINGE.....	23	<i>megestrol acetate oral suspension 40</i>	
KISQALI (200 MG DOSE).....	113	<i>mg/ml, 625 mg/5ml</i> .....	140
KISQALI (400 MG DOSE).....	113	MEKINIST.....	141
KISQALI (600 MG DOSE).....	113	MEKTOVI.....	26
KISQALI FEMARA (200 MG DOSE).....	113	<i>mifepristone oral tablet 300 mg</i> .....	114
KISQALI FEMARA (400 MG DOSE).....	113	<i>miglustat</i> .....	143
KISQALI FEMARA (600 MG DOSE).....	113	<i>minoxidil oral</i> .....	139
KORLYM.....	114	MULTAQ.....	139
KOSELUGO.....	115	MYALEPT.....	144
KRAZATI.....	116	MYCAPSSA.....	145

MYFEMBREE.....	254	OGSIVEO.....	160
MYTESI.....	146	OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG.....	161
NAMZARIC.....	147	ONUREG.....	162
NATPARA.....	148	OPFOLDA.....	163
NAYZILAM.....	100	OPSUMIT.....	65
NERLYNX.....	149	ORENITRAM.....	164
NEULASTA ONPRO.....	177	ORENITRAM MONTH 1.....	164
NEULASTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	177	ORENITRAM MONTH 2.....	164
NEUPOGEN INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6ML.....	75	ORENITRAM MONTH 3.....	164
NEUPOGEN INJECTION SOLUTION PREFILLED SYRINGE.....	75	ORFADIN ORAL SUSPENSION.....	152
NEXLETOL.....	18	ORIAHNN.....	254
NEXLIZET.....	18	ORLISSA ORAL TABLET 150 MG, 200 MG..	166
NINLARO.....	151	ORKAMBI.....	167
<i>nitisinone</i> .....	152	ORLADEYO.....	90
NIVESTYM.....	75	ORSERDU.....	168
NORDITROPIN FLEXPOR SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	88	OSMOLEX ER ORAL TABLET ER 24 HOUR THERAPY PACK.....	8
NUBEQA.....	191	OSMOLEX ER ORAL TABLET EXTENDED RELEASE 24 HOUR 129 MG, 193 MG.....	8
NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	153	OTEZLA.....	23
NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML.....	153	OTREXUP SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.4ML, 12.5 MG/0.4ML, 15 MG/0.4ML, 17.5 MG/0.4ML, 20 MG/0.4ML, 22.5 MG/0.4ML, 25 MG/0.4ML.....	142
NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED.....	153	OXBRYTA.....	169
NUDEXTA.....	155	OXERVATE.....	170
NUPLAZID ORAL CAPSULE.....	156	PALYNZIQ.....	172
NUPLAZID ORAL TABLET 10 MG.....	156	PANRETIN.....	173
NURTEC.....	40	<i>pazopanib hcl</i> .....	272
NUTROPIN AQ NUSPIN 10 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	88	PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML.....	184
NUTROPIN AQ NUSPIN 20 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	88	PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	184
NUTROPIN AQ NUSPIN 5 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	88	PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG.....	178
OALIVA ORAL TABLET 10 MG, 5 MG.....	157	<i>pioglitazone hcl</i> .....	139
OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 10 GM/100ML, 10 GM/200ML, 2 GM/20ML, 2.5 GM/50ML, 20 GM/200ML, 5 GM/100ML, 5 GM/50ML.....	95	PIQRAY (200 MG DAILY DOSE).....	179
ODOMZO.....	158	PIQRAY (250 MG DAILY DOSE).....	179
OFEV.....	159	PIQRAY (300 MG DAILY DOSE).....	179
		<i>pirfenidone oral tablet 267 mg, 801 mg....</i>	180
		POMALYST.....	181

PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	175	RETEVMO ORAL CAPSULE 40 MG, 80 MG..	199
PRETOMANID.....	182	REVLIMID.....	119
PREVYMIS ORAL.....	183	REZLIDHIA.....	200
PRIVIGEN.....	95	REZUROCK.....	201
PROCYSBI.....	185	RIVFLOZA.....	202
PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED.....	6	ROZLYTREK.....	203
PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	186	RUBRACA.....	204
PROMACTA ORAL PACKET.....	188	RUCONEST.....	89
PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG.....	188	RYDAPT.....	205
<i>promethazine hcl oral syrup</i> .....	190	<i>sajazir subcutaneous solution prefilled syringe</i> .....	89
<i>promethazine hcl oral tablet</i> .....	190	<i>sapropterin dihydrochloride oral packet</i> ....	206
<i>promethazine hcl rectal suppository 12.5 mg, 25 mg</i> .....	190	<i>sapropterin dihydrochloride oral tablet</i> ....	206
PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG.....	190	SCEMBLIX ORAL TABLET 20 MG, 40 MG....	207
PYRUKYND.....	192	SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG.....	209
PYRUKYND TAPER PACK ORAL TABLET THERAPY PACK 5 MG, 7 X 20 MG & 7 X 5 MG, 7 X 50 MG & 7 X 20 MG.....	192	SIGNIFOR.....	210
QINLOCK.....	193	<i>sildenafil citrate oral suspension reconstituted</i> .....	176
QULIPTA.....	40	<i>sildenafil citrate oral tablet 20 mg</i> .....	176
QUVIVIQ.....	165	SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	23
RADICAVA ORS.....	194	SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	23
RADICAVA ORS STARTER KIT.....	194	<i>simvastatin oral tablet 80 mg</i> .....	211
RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML.....	142	SIRTURO.....	212
RAVICTI.....	195	SIVEXTRO.....	213
RECORLEV.....	196	SKYCLARYS.....	214
RELYVRIO.....	198	<i>sofosbuvir-velpatasvir</i> .....	215
REPATHA.....	175	SOGROYA.....	88
REPATHA PUSHTRONEX SYSTEM.....	175	SOHONOS.....	216
REPATHA SURECLICK.....	175	SOMAVERT.....	217
RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML.....	70	<i>sorafenib tosylate</i> .....	150
		SOTYKTU.....	23
		SOVALDI ORAL PACKET.....	218
		SOVALDI ORAL TABLET 200 MG, 400 MG..	218
		SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG.....	219
		STIVARGA.....	220
		SUCRAID.....	221
		<i>sunitinib malate</i> .....	222
		SUNOSI ORAL TABLET 150 MG, 75 MG.....	223
		SYMDEKO.....	224

SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	184	TRIKAFTA ORAL TABLET THERAPY PACK 100-50-75 & 150 MG, 50-25-37.5 & 75 MG .....	247
SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	184	TRIKAFTA ORAL THERAPY PACK.....	247
SYMPROIC.....	225	TRUQAP.....	248
SYNAREL.....	226	TUKYSA ORAL TABLET 150 MG, 50 MG.....	249
SYNDROS.....	59	TURALIO.....	250
SYNRIBO.....	227	TYMLOS.....	251
TABRECTA.....	228	UBRELVY.....	40
<i>tadalafil (pah)</i> .....	176	UDENYCA.....	177
TAFINLAR.....	230	UDENYCA ONBODY.....	177
TAGRISSO.....	231	UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG.....	253
TAKHZYRO SUBCUTANEOUS SOLUTION.....	90	UPTRAVI TITRATION.....	253
TAKHZYRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 300 MG/2ML.....	90	VABOMERE.....	184
TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG.....	232	VALCHLOR.....	255
TARPEYO.....	233	VALTOCO 10 MG DOSE.....	100
TASIGNA.....	234	VALTOCO 15 MG DOSE.....	100
<i>tasimelteon</i> .....	235	VALTOCO 20 MG DOSE.....	100
TAVALISSE ORAL TABLET 100 MG, 150 MG.....	236	VALTOCO 5 MG DOSE.....	100
TAVNEOS.....	237	VANFLYTA.....	256
<i>tazarotene external cream</i> .....	184	VELSIPITY.....	23
<i>tazarotene external gel</i> .....	184	VEMLIDY.....	184
TAZORAC EXTERNAL CREAM 0.05 %.....	184	VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG.....	257
TAZVERIK.....	238	VENCLEXTA STARTING PACK.....	257
TEGSEDI.....	239	VENTAVIS.....	258
TENCON ORAL TABLET 50-325 MG.....	29	VEOZAH.....	259
TEPMETKO.....	240	VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG.....	260
<i>teriparatide (recombinant)</i> .....	241	VERZENIO.....	262
<i>testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)</i> .....	243	VIBERZI.....	263
<i>testosterone transdermal solution</i> .....	243	VIJOICE ORAL TABLET THERAPY PACK 125 MG, 200 & 50 MG, 50 MG.....	264
<i>tetrabenazine oral tablet 12.5 mg, 25 mg</i> .....	268	VITRAKVI ORAL CAPSULE 100 MG, 25 MG.....	265
TIBSOVO.....	244	VITRAKVI ORAL SOLUTION.....	265
<i>tolvaptan</i> .....	245	VIVJOA.....	266
TRACLEER ORAL TABLET SOLUBLE.....	65	VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG.....	267
TREMFYA.....	23	VONJO.....	269
		VOQUEZNA ORAL TABLET 10 MG, 20 MG.....	270
		VOSEVI.....	271
		VOWST.....	273



VRAYLAR ORAL CAPSULE.....	274	ZONTIVITY .....	290
VRAYLAR ORAL CAPSULE THERAPY PACK...	274	ZORBTIVE .....	291
VTAMA .....	246	ZORYVE EXTERNAL CREAM .....	246
VUMERITY .....	82	ZTALMY .....	292
VYNDAMAX .....	229	ZURZUVAE .....	293
VYNDAQEL.....	229	ZYDELIG .....	294
WAKIX ORAL TABLET 17.8 MG, 4.45 MG ....	275	ZYKADIA ORAL TABLET .....	295
WELIREG .....	276		
XALKORI .....	277		
XERMELO .....	278		
XGEVA .....	279		
XOLAIR .....	280		
XOSPATA .....	282		
XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG .....	283		
XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG .....	283		
XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG .....	283		
XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG .....	283		
XPOVIO (60 MG TWICE WEEKLY) .....	283		
XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG .....	283		
XPOVIO (80 MG TWICE WEEKLY) .....	283		
XTANDI .....	191		
XURIDEN .....	284		
XYREM .....	171		
XYWAV .....	171		
<i>zaleplon</i> .....	208		
ZEBUTAL ORAL CAPSULE 50-325-40 MG .....	29		
ZEJULA ORAL CAPSULE .....	285		
ZEJULA ORAL TABLET .....	285		
ZELBORAF .....	47		
ZEMAIRA .....	6		
ZEPOSIA .....	23		
ZEPOSIA 7-DAY STARTER PACK .....	23		
ZEPOSIA STARTER KIT ORAL CAPSULE THERAPY PACK 0.23MG & 0.46MG 0.92MG(21) .....	23		
ZERBAXA .....	286		
ZILBRYSQ .....	287		
ZOKINVY ORAL CAPSULE 50 MG, 75 MG ....	289		
<i>zolpidem tartrate oral tablet</i> .....	208		